1
|
Ingen-Housz-Oro S, Guichard E, Milpied B, Bensaid B, Collet E, Barbaud A, Le Duff F, Tétart F, Soria A, Machet L, Descamps V, Monestier S, Pasteur J, Morice C, Chaby G, Colin A, Grégoire L, Allanore L, Giraudeau B, Chosidow O. Topical versus oral corticosteroids in moderate drug reaction with eosinophilia and systemic symptoms (DRESS): a multicenter randomized clinical trial. J Am Acad Dermatol 2024:S0190-9622(24)00745-X. [PMID: 38754628 DOI: 10.1016/j.jaad.2024.04.077] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/11/2024] [Revised: 04/04/2024] [Accepted: 04/22/2024] [Indexed: 05/18/2024]
Affiliation(s)
- Saskia Ingen-Housz-Oro
- Dermatology department, Henri Mondor hospital, AP-HP, Créteil, France; French Investigators for Skin Adverse Reactions to Drugs (FISARD) group, Paris, France; Refence center for toxic bullous diseases and severe drug reactions TOXIBUL, Créteil, France; Univ Paris Est Créteil EpiDermE, Créteil, France
| | | | - Brigitte Milpied
- French Investigators for Skin Adverse Reactions to Drugs (FISARD) group, Paris, France; Dermatology department, CHU Bordeaux, Bordeaux, France
| | - Benoit Bensaid
- French Investigators for Skin Adverse Reactions to Drugs (FISARD) group, Paris, France; Dermatology department, CHU Edouard Herriot, Lyon, France
| | - Evelyne Collet
- French Investigators for Skin Adverse Reactions to Drugs (FISARD) group, Paris, France; Dermatology department, CHU Dijon, Dijon, France
| | - Annick Barbaud
- French Investigators for Skin Adverse Reactions to Drugs (FISARD) group, Paris, France; Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, AP-HP, Hôpital Tenon, Département de dermatologie et allergologie, Paris France
| | | | - Florence Tétart
- French Investigators for Skin Adverse Reactions to Drugs (FISARD) group, Paris, France; Dermatology department, CHU Charles Nicolle, Rouen, France
| | - Angèle Soria
- French Investigators for Skin Adverse Reactions to Drugs (FISARD) group, Paris, France; Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, AP-HP, Hôpital Tenon, Département de dermatologie et allergologie, Paris France
| | | | - Vincent Descamps
- French Investigators for Skin Adverse Reactions to Drugs (FISARD) group, Paris, France; Dermatology department, Bichat hospital, APHP, Paris, France
| | | | - Justine Pasteur
- French Investigators for Skin Adverse Reactions to Drugs (FISARD) group, Paris, France; Dermatology department, Hôpital Estaing, CHU Clermont-Ferrand, Clermont-Ferrand, France
| | - Cécile Morice
- French Investigators for Skin Adverse Reactions to Drugs (FISARD) group, Paris, France; Dermatology department, CHU Caen, Caen, France
| | | | - Audrey Colin
- Dermatology department, Henri Mondor hospital, AP-HP, Créteil, France
| | - Laëtitia Grégoire
- Unité de Recherche Clinique, Henri Mondor hospital, APHP, Créteil, France
| | - Laurence Allanore
- Dermatology department, Henri Mondor hospital, AP-HP, Créteil, France; French Investigators for Skin Adverse Reactions to Drugs (FISARD) group, Paris, France
| | - Bruno Giraudeau
- INSERM CIC1415, CHRU de Tours, Tours, France; Université de Tours, Université de Nantes, INSERM, SPHERE U1246, Tours, France
| | - Olivier Chosidow
- French Investigators for Skin Adverse Reactions to Drugs (FISARD) group, Paris, France; Facial Dermatosis Clinic, ENT Department Hôpital Universitaire Pitié-Salpêtrière, AP-HP, Paris, France.
| |
Collapse
|
2
|
Sambourg J, Maravic M, Descamps V. Excess risk of candidiasis with IL-17 inhibitors: A retrospective cohort study using retail pharmacies drug dispensing data. J Eur Acad Dermatol Venereol 2023. [PMID: 38108508 DOI: 10.1111/jdv.19759] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/29/2023] [Accepted: 12/07/2023] [Indexed: 12/19/2023]
Affiliation(s)
| | - Milka Maravic
- General Management, IQVIA, Courbevoie, France
- Department of Rheumatology, Lariboisière Hospital, AP-HP, Paris, France
| | - Vincent Descamps
- Department of Dermatology, Bichat Hospital, AP-HP, Paris, France
| |
Collapse
|
3
|
Marcombes C, Ingen-Housz-Oro S, Dezoteux F, Staumont-Sallé D, Milpied B, Tetart F, de Prost N, Fourati S, Ortonne N, Kasimir F, Prusty BK, Descamps V. Retrospective study on the association of human herpesvirus reactivation with severe DRESS: A description of blood and skin reactivations. J Eur Acad Dermatol Venereol 2023; 37:2550-2557. [PMID: 37591509 DOI: 10.1111/jdv.19425] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/27/2023] [Accepted: 07/17/2023] [Indexed: 08/19/2023]
Abstract
BACKGROUND Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) is a severe adverse event (mortality of 10%). Its pathophysiology involves herpesviruses, particularly HHV-6, but the exact mechanisms are still poorly understood. OBJECTIVE To describe severe cases of DRESS and especially their association with herpesvirus reactivation. METHODS This study was a multicentre case series conducted between 2007 and 2021 at five University Hospital Centres in France. The study included patients who had severe DRESS, which was defined as death, transfer to the intensive care unit (ICU), or severe damage to internal organs. We excluded patients without blood PCR sample, without a drug formally attributed or with RegiSCAR score < 6. We collected data on severity, causative drug, associated visceral damage and results of viral blood PCRs. HHV-6 reactivation was studied in skin biopsies by detection of small non-coding transcripts (HHV-6 miR-aU14) and a late viral protein (GP82/105). RESULTS Fifty-two patients were included (29 female, median age 62, interquartile range (IQR) [37;72]). Eight patients (15%) died, 13 (27%) were admitted to ICU. Most patients (n = 34; 65%) had multisystem involvement: most frequent was liver (n = 46; 88%), then renal failure (n = 24; 46%). Forty patients (77%) had at least one blood viral reactivation among HHV-6, EBV or CMV, of which 21 (53%) had at least two. Median time of blood HHV-6 reactivation was 24 days (IQR [20;35]). HHV-6 reactivation was demonstrated in 15 out of 20 skin biopsies, with a median time of 11 days [9;17]. CONCLUSIONS We confirmed the high rate of HHV-6 reactivation in severe DRESS and demonstrated cutaneous HHV-6 reactivation using small non-coding transcripts (HHV-6 miR-aU14), which preceded viral PCR positivity in blood. These results suggest that HHV-6 reactivation during DRESS may start in skin. Furthermore, search for miR-aU14 in skin biopsy could become a useful diagnostic tool for early detection of HHV-6 reactivation.
Collapse
Affiliation(s)
- C Marcombes
- Department of Dermatology, AP-HP, Bichat Hospital, Paris, France
| | - S Ingen-Housz-Oro
- Department of Dermatology, AP-HP, Henri-Mondor Hospital, Créteil, France
- Reference Center for Toxic Bullous Dermatoses and Severe Drug Reactions TOXIBUL, Créteil, France
- Epiderme, Paris Est Créteil University, Créteil, France
- FISARD Study Group (French Investigators for Skin Adverse Reactions to Drugs) of the French Dermatology Society, Paris, France
| | - F Dezoteux
- FISARD Study Group (French Investigators for Skin Adverse Reactions to Drugs) of the French Dermatology Society, Paris, France
- Department of Dermatology, CHU Lille, Univ Lille, INSERM U1286, Lille Inflammation Translational Research Institute (INFINITE), Lille, France
| | - D Staumont-Sallé
- FISARD Study Group (French Investigators for Skin Adverse Reactions to Drugs) of the French Dermatology Society, Paris, France
- Department of Dermatology, CHU Lille, Univ Lille, INSERM U1286, Lille Inflammation Translational Research Institute (INFINITE), Lille, France
| | - B Milpied
- Reference Center for Toxic Bullous Dermatoses and Severe Drug Reactions TOXIBUL, Créteil, France
- FISARD Study Group (French Investigators for Skin Adverse Reactions to Drugs) of the French Dermatology Society, Paris, France
- Department of Dermatology, UHC Bordeaux, Bordeaux, France
| | - F Tetart
- Reference Center for Toxic Bullous Dermatoses and Severe Drug Reactions TOXIBUL, Créteil, France
- FISARD Study Group (French Investigators for Skin Adverse Reactions to Drugs) of the French Dermatology Society, Paris, France
- Department of Dermatology, UHC Rouen, Rouen, France
| | - N de Prost
- Reference Center for Toxic Bullous Dermatoses and Severe Drug Reactions TOXIBUL, Créteil, France
- Intensive Care Unit, AP-HP, Henri-Mondor Hospital, Créteil, France
| | - S Fourati
- Virology Department, AP-HP, Henri-Mondor Hospital, Créteil, France
| | - N Ortonne
- Department of Pathology, Henri-Mondor Hospital, Créteil, France
| | - F Kasimir
- Institute for Virology and Immunobiology, Julius-Maximilians-UniversitätWürzburg, Würzburg, Germany
| | - B K Prusty
- Institute for Virology and Immunobiology, Julius-Maximilians-UniversitätWürzburg, Würzburg, Germany
| | - V Descamps
- Department of Dermatology, AP-HP, Bichat Hospital, Paris, France
- FISARD Study Group (French Investigators for Skin Adverse Reactions to Drugs) of the French Dermatology Society, Paris, France
| |
Collapse
|
4
|
Cohen E, Lheure C, Ingen-Housz-Oro S, Hotz C, Bettuzzi T, Chasset F, Descamps V, Deschamps L, Mahevas M, Terrier B, Sohier P, Guegan S, Kramkimel N, Darbord D, Chanal J, Oulès B, Aractingi S, Seta V, Dupin N. Which first-line treatment for cutaneous sarcoidosis? A retrospective study of 120 patients. Eur J Dermatol 2023; 33:680-685. [PMID: 38465550 DOI: 10.1684/ejd.2023.4584] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/12/2024]
Abstract
Sarcoidosis is a systemic disease that affects the skin in about 25% of patients. The treatment of cutaneous sarcoidosis is guided by the extent of lesions, associated symptoms and organ involvement. To evaluate rates of response to various potential first-line treatments for cutaneous sarcoidosis during the year following treatment initiation. This retrospective multicentre study included 120 patients with cutaneous sarcoidosis. Treatment response was assessed retrospectively from the patients' medical records. Univariate logistic regression analysis, with an estimation of unadjusted odds ratios (OR) and their 95% CI ,was performed to identify factors associated with complete cutaneous remission (CR), followed by multivariate logistic regression analysis. At one year, 43 of the 120 (36%) included patients had CR. The best response rates were obtained with oral corticosteroids (12/21, 57%), followed by a combination of hydroxychloroquine and topical steroids (6/13, 46%). In multivariate analysis, lupus pernio was the only predictor of a poor cutaneous response. We suggest the use of a combination of hydroxychloroquine and topical steroids as an optimal first-line treatment for cutaneous sarcoidosis, given the known adverse effects of systemic corticosteroids.
Collapse
Affiliation(s)
- Elisabeth Cohen
- Department of Dermatology, APHP, Cochin Hospital, Paris, France
| | - Coralie Lheure
- Department of Dermatology, APHP, Cochin Hospital, Paris, France
| | - Saskia Ingen-Housz-Oro
- Department of Dermatology, APHP, Mondor Hospital, Paris, France, EpiDermE, University Paris Est Créteil, Créteil, France
| | - Claire Hotz
- Department of Dermatology, APHP, Mondor Hospital, Paris, France
| | - Thomas Bettuzzi
- Department of Dermatology, APHP, Mondor Hospital, Paris, France
| | | | | | - Lydia Deschamps
- Department of Pathology, APHP, Bichat Hospital, Paris, France
| | - Matthieu Mahevas
- Department of Internal Medicine, APHP, Mondor Hospital, Paris, France
| | - Benjamin Terrier
- Department of Internal Medicine, APHP, Cochin Hospital, Paris, France
| | - Pierre Sohier
- Department of Pathology, APHP, Cochin Hospital, Paris, France
| | - Sarah Guegan
- Department of Dermatology, APHP, Cochin Hospital, Paris, France
| | - Nora Kramkimel
- Department of Dermatology, APHP, Cochin Hospital, Paris, France
| | | | - Johan Chanal
- Department of Dermatology, APHP, Cochin Hospital, Paris, France
| | - Benedicte Oulès
- Department of Dermatology, APHP, Cochin Hospital, Paris, France
| | - Selim Aractingi
- Department of Dermatology, APHP, Cochin Hospital, Paris, France
| | - Vannina Seta
- Department of Dermatology, APHP, Cochin Hospital, Paris, France
| | - Nicolas Dupin
- Department of Dermatology, APHP, Cochin Hospital, Paris, France
| |
Collapse
|
5
|
Charriot J, Descamps V, Jankowski R, Maravic M, Bourdin A. Multiple Biologics for Multiple T2 Diseases: A Pharmacoepidemiological Algorithm for Sorting Out Patients by Indication. J Asthma Allergy 2023; 16:1287-1295. [PMID: 38050615 PMCID: PMC10693777 DOI: 10.2147/jaa.s424152] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/17/2023] [Accepted: 11/07/2023] [Indexed: 12/06/2023] Open
Abstract
Background Several biologics (Bx) and targeted synthetic drugs (TSD) exist to treat T2 diseases, including chronic spontaneous urticaria (CSU), severe asthma (SA), chronic rhinosinusitis with nasal polyposis (CRSwNP) or atopic dermatitis (AD). Objective To identify patients treated with Bx/TSD from a dynamic dispensing database using an algorithm-based methodology. Methods We used the LRx database (Lifelink Treatment dynamics, IQVIA) which covers nearly 45% of the French retail pharmacies. Patients who had at least one Bx/TSD dispensing from April 2021 to March 2022 were included. An algorithm was designed to determine the indication of the Bx/TSD prescription analyzing all previous drug dispensation since March 2012 following a 3-steps procedure. Results A total of 21,677 patients received at least one Bx/TSD between March 2021 and April 2022. The algorithm identified 91.7% (n = 19,884) patients with a T2 disease (AD = 18.4%, CRSwNP = 1.5%, SA = 59.5%, and CSU = 12.4%), the rest having either an association of diseases (1%) or an undetermined one (7.3%). SA was the main reason for Bx/TSD initiation (52%), followed by AD (29%), CSU (14%) and CRSwNP (5%). For SA patients already under biologic at entry, omalizumab was the most frequently prescribed (48%) followed by benralizumab, mepolizumab (22% each) and dupilumab (8%). Dupilumab was mostly prescribed for AD patients (89% for patient-initiated vs 96% for patient-renewed) followed by baricitinib. Conclusion The algorithm was able to identify patients with T2 diseases under Bx/TSD treatments. This tool may help to follow the evolution of prescription patterns in the future.
Collapse
Affiliation(s)
- Jeremy Charriot
- Department of Respiratory Diseases, University of Montpellier, PhyMedExp, INSERM, CNRS UMR, CHU Montpellier, Montpellier, France
| | - Vincent Descamps
- Department of Dermatology, Hôpital Bichat AP-HP Nord - University of Paris Cité, Paris, France
| | - Roger Jankowski
- Service d’ORL et de Chirurgie Cervico-Faciale, CHRU – Institut Louis Mathieu, Vandoeuvre, France
| | - Milka Maravic
- Department of Rheumatology, Lariboisière Hospital Lariboisière, APHP Nord, Paris, France
- General Management, IQVIA, Paris, France
| | - Arnaud Bourdin
- Department of Respiratory Diseases, University of Montpellier, PhyMedExp, INSERM, CNRS UMR, CHU Montpellier, Montpellier, France
| |
Collapse
|
6
|
Lutz W, Bertin C, Merlant M, Mailhe M, Le Hingrat Q, Descamps V, Guilhou T, Maisonobe L, Yazdanpanah Y, Deschamps L, Charpentier C, Lariven S. Mpox presenting as a chronic cutaneous ulcer in a patient with advanced HIV infection. Clin Exp Dermatol 2023; 48:1364-1365. [PMID: 37595137 DOI: 10.1093/ced/llad258] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/30/2023] [Accepted: 08/16/2023] [Indexed: 08/20/2023]
Abstract
We report a case of an atypical presentation of Mpox infection in a patient with advanced HIV. The lesion was a chronic back ulcer that grew over 4 months before a diagnosis was made, when a second lesion appeared on the neck.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | | | | | - Lydia Deschamps
- Pathology Department, AP-HP, Bichat-Claude Bernard Hospital, University Paris Cité, Paris,France
| | | | | |
Collapse
|
7
|
Reichert C, Baldini C, Mezghani S, Maubec E, Longvert C, Mortier L, Quereux G, Jannic A, Machet L, de Quatrebarbes J, Nardin C, Beneton N, Amini Adle M, Funck-Brentano E, Descamps V, Hachon L, Malissen N, Baroudjian B, Brunet-Possenti F. Combined Nivolumab and Ipilimumab in Octogenarian and Nonagenarian Melanoma Patients. Cancers (Basel) 2023; 15:4330. [PMID: 37686606 PMCID: PMC10486537 DOI: 10.3390/cancers15174330] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/16/2023] [Revised: 08/13/2023] [Accepted: 08/24/2023] [Indexed: 09/10/2023] Open
Abstract
Data regarding elderly melanoma patients treated with anti-PD-1 or anti-CTLA-4 antibodies are in favor of tolerability outcomes that are similar to those of younger counterparts. However, there are very few studies focusing on elderly patients receiving nivolumab combined with ipilimumab (NIVO + IPI). Here, we ask what are the current prescribing patterns of NIVO + IPI in the very elderly population and analyze the tolerance profile. This French multicenter retrospective study was conducted on 60 melanoma patients aged 80 years and older treated with NIVO + IPI between January 2011 and June 2022. The mean age at first NIVO + IPI administration was 83.7 years (range: 79.3-93.3 years). Fifty-five patients (92%) were in good general condition and lived at home. Two dosing regimens were used: NIVO 1 mg/kg + IPI 3 mg/kg Q3W (NIVO1 + IPI3) in 27 patients (45%) and NIVO 3 mg/kg + IPI 1 mg/kg Q3W (NIVO3 + IPI1) in 33 patients (55%). NIVO + IPI was a first-line treatment in 39 patients (65%). The global prevalence of immune-related adverse events was 63% (38/60), with 27% (16/60) being of grade 3 or higher. Grade ≥ 3 adverse events were less frequent in patients treated with NIVO3 + IPI1 compared with those treated with NIVO1 + IPI3 (12% versus 44%, p = 0.04). In conclusion, the prescribing patterns of NIVO + IPI in very elderly patients are heterogeneous in terms of the dosing regimen and line of treatment. The safety profile of NIVO + IPI is reassuring; whether or not the low-dose regimen NIVO3 + IPI1 should be preferred over NIVO1 + IPI3 in patients aged 80 years or older remains an open question.
Collapse
Affiliation(s)
- Constance Reichert
- Department of Dermatology, Hôpital Bichat AP-HP, Université Paris Cité, 75018 Paris, France; (C.R.); (V.D.)
| | - Capucine Baldini
- Drug Development Department, Institut Gustave Roussy, CNRS-UMS 3655 and INSERM US23, 94805 Villejuif, France;
| | - Sarah Mezghani
- Department of Imaging, Institut Curie, PSL Research University, 75005 Paris, France;
| | - Eve Maubec
- Department of Dermatology, Hôpital Avicenne AP-HP, Université Sorbonne Paris Nord—Campus de Bobigny, 93000 Bobigny, France;
| | - Christine Longvert
- Department of Dermatology, EA4340-BECCOH, Hôpital Ambroise Paré APHP, Université Paris-Saclay, 92100 Boulogne-Billancourt, France; (C.L.); (E.F.-B.)
| | - Laurent Mortier
- Department of Dermatology, Claude Huriez Hospital, Lille University, Inserm U1189, 59000 Lille, France;
| | - Gaëlle Quereux
- Department of Dermatology, Centre Hospitalier Universitaire de Nantes, CIC 1413, INSERM, Immunology and New Concepts in ImmunoTherapy, INCIT, UMR 1302, Nantes University, 44000 Nantes, France;
| | - Arnaud Jannic
- Dermatology Department, Hôpital Henri Mondor AP-HP, 94000 Créteil, France;
| | - Laurent Machet
- Department of Dermatology, Tours University Hospital, 37000 Tours, France;
| | - Julie de Quatrebarbes
- Department of Dermatology, Centre Hospitalier Annecy-Genevois, 74370 Annecy, France;
| | - Charlée Nardin
- Université de Franche-Comté, CHU Besançon, EFS, INSERM, UMR RIGHT, 25000 Besançon, France;
| | - Nathalie Beneton
- Department of Dermatology, Centre Hospitalier du Mans, 72037 Le Mans, France;
| | - Mona Amini Adle
- Oncodermatology Department Centre Léon Bérard, 69008 Lyon, France;
| | - Elisa Funck-Brentano
- Department of Dermatology, EA4340-BECCOH, Hôpital Ambroise Paré APHP, Université Paris-Saclay, 92100 Boulogne-Billancourt, France; (C.L.); (E.F.-B.)
| | - Vincent Descamps
- Department of Dermatology, Hôpital Bichat AP-HP, Université Paris Cité, 75018 Paris, France; (C.R.); (V.D.)
| | - Lorry Hachon
- Department of Pharmacy, Hôpital Bichat, AP-HP, 75018 Paris, France;
| | - Nausicaa Malissen
- Dermatology and Skin Cancer Department, APHM, CRCM Inserm U1068, CNRS U7258, CHU Timone, Aix Marseille University, 13007 Marseille, France;
| | - Barouyr Baroudjian
- Department of Dermato-Oncology, Hôpital Saint-Louis AP-HP, Inserm U976, Université Paris Cité, 75010 Paris, France;
| | - Florence Brunet-Possenti
- Department of Dermatology, Hôpital Bichat AP-HP, Université Paris Cité, 75018 Paris, France; (C.R.); (V.D.)
| |
Collapse
|
8
|
Blanchet FX, Rahi M, Merlant M, Gare M, Brunet-Possenti F, Descamps V, Bouscarat F. Genital Pseudotumor as a Manifestation of Mpox Virus Infection. JAMA Dermatol 2023; 159:563-564. [PMID: 36947032 DOI: 10.1001/jamadermatol.2023.0307] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/23/2023]
Abstract
This case report describes a 37-year-old man with a 1-week history of a genital nodule that rapidly ulcerated and with concomitant fever 2 days after anal intercourse.
Collapse
Affiliation(s)
| | - Mayda Rahi
- Infectious Diseases Department, Bichat-Claude Bernard Hospital, University of Paris, Paris, France
| | - Marie Merlant
- Dermatology Department, Bichat-Claude Bernard Hospital, University of Paris, Paris, France
| | - Mathilde Gare
- Infectious Diseases Department, Bichat-Claude Bernard Hospital, University of Paris, Paris, France
| | | | - Vincent Descamps
- Dermatology Department, Bichat-Claude Bernard Hospital, University of Paris, Paris, France
| | - Fabrice Bouscarat
- Dermatology Department, Bichat-Claude Bernard Hospital, University of Paris, Paris, France
| |
Collapse
|
9
|
Chalali F, Merlant M, Truong A, Ghosn J, Phung BC, Mollo B, Perrineau S, Rahi M, Fidouh-Houhou N, Ferré VM, Brunet-Possenti F, Descamps V, Bouscarat F, Yazdanpanah Y, Deschamps L, Bertin C. Histological Features Associated With Human Mpox Virus Infection in 2022 Outbreak in a Nonendemic Country. Clin Infect Dis 2023; 76:1132-1135. [PMID: 36318605 DOI: 10.1093/cid/ciac856] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/18/2022] [Revised: 10/17/2022] [Accepted: 10/26/2022] [Indexed: 11/07/2022] Open
Abstract
Skin histology of papules and pustules from 5 men having sex with men with mpox infection showed viral intracytoplasmic cytopathic changes, interface dermatitis, marked inflammatory dermic infiltrate including superficial neutrophils and perivascular and periadnexal deep lymphocytes. Histologic description of mpox lesions improves our understanding about clinical presentations and may have some therapeutic implications.
Collapse
Affiliation(s)
- Faris Chalali
- Dermatology Department, AP-HP, Bichat-Claude Bernard Hospital, University of Paris, Paris, France
| | - Marie Merlant
- Dermatology Department, AP-HP, Bichat-Claude Bernard Hospital, University of Paris, Paris, France
| | - Audrey Truong
- Pathology Department, AP-HP, Bichat-Claude Bernard Hospital, University of Paris, Paris, France
| | - Jade Ghosn
- Infectious Diseases Department, AP-HP, Bichat-Claude Bernard Hospital, University of Paris, Paris, France
| | - Bao-Chau Phung
- Infectious Diseases Department, AP-HP, Bichat-Claude Bernard Hospital, University of Paris, Paris, France
| | - Bastien Mollo
- Infectious Diseases Department, AP-HP, Bichat-Claude Bernard Hospital, University of Paris, Paris, France
| | - Ségolène Perrineau
- Infectious Diseases Department, AP-HP, Bichat-Claude Bernard Hospital, University of Paris, Paris, France
| | - Mayda Rahi
- Infectious Diseases Department, AP-HP, Bichat-Claude Bernard Hospital, University of Paris, Paris, France
| | - Nadhira Fidouh-Houhou
- Virology Department, AP-HP, Bichat-Claude Bernard Hospital, University of Paris, INSERM, IAME, UMR 1137, Paris, France
| | - Valentine Marie Ferré
- Virology Department, AP-HP, Bichat-Claude Bernard Hospital, University of Paris, INSERM, IAME, UMR 1137, Paris, France
| | - Florence Brunet-Possenti
- Dermatology Department, AP-HP, Bichat-Claude Bernard Hospital, University of Paris, Paris, France
| | - Vincent Descamps
- Dermatology Department, AP-HP, Bichat-Claude Bernard Hospital, University of Paris, Paris, France
| | - Fabrice Bouscarat
- Dermatology Department, AP-HP, Bichat-Claude Bernard Hospital, University of Paris, Paris, France
| | - Yazdan Yazdanpanah
- Infectious Diseases Department, AP-HP, Bichat-Claude Bernard Hospital, University of Paris, Paris, France
| | - Lydia Deschamps
- Pathology Department, AP-HP, Bichat-Claude Bernard Hospital, University of Paris, Paris, France
| | - Chloé Bertin
- Infectious Diseases Department, AP-HP, Bichat-Claude Bernard Hospital, University of Paris, Paris, France
| |
Collapse
|
10
|
Skayem C, Majda A, Gary C, Hemery F, Mahé E, Caux F, Dupin N, Senet P, Greder-Belan A, Hillion B, Meni C, Saiag P, Bellaud G, Bleibtreu A, Lariven S, Bollens D, Descamps V, Molina JM, Bouchaud O, Vittecoq D, Do-Pham G, Foulet F, Botterel F, Chosidow O, Bernigaud C. Severe Scabies: A French Multi-centre Study Involving 95 Patients with Crusted and Profuse Disease and Review of the Literature. Acta Derm Venereol 2023; 103:adv00878. [PMID: 36861856 PMCID: PMC9993169 DOI: 10.2340/actadv.v103.5351] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/21/2022] [Accepted: 02/01/2023] [Indexed: 03/03/2023] Open
Abstract
The aim of this multi-centre French retrospective study was to identify severe, i.e. crusted and profuse, scabies patients. Records were retrieved from 22 Dermatology or Infectious Diseases departments in the Ile-de-France from January 2009 to January 2015 to characterize epidemiology, demography, diagnosis, contributing factors, treatment features, and outcomes in severe scabies. A total of 95 inpatients (57 crusted and 38 profuse) were included. A higher number of cases was observed among elderly patients (>75 years), mostly living in institutions. Thirteen patients (13.6%) reported a history of previously treated scabies. Sixty-three patients (66.3%) had been seen by a previous practitioner for the current episode (up to 8 previous visits). Initial misdiagnosis (e.g. eczema, prurigo, drug-related eruptions, psoriasis) was documented in 41 patients (43.1%). Fifty-eight patients (61%) had already received 1 or more previous treatments for their current episode. Forty percent received corticosteroids or acitretin for an initial diagnosis of eczema or psoriasis. Median time from the onset of symptoms to the diagnosis of severe scabies was 3 months (range 0.3-22). Itch was present in all patients at diagnosis. Most patients (n=84, 88.4%) had comorbidities. Diagnostic and therapeutic approaches varied. Complications occurred in 11.5% of cases. To date, there is no consensus for diagnosis and treatment, and future standardization of is required for optimal management.
Collapse
Affiliation(s)
- Charbel Skayem
- Dermatology Department, Assistance Publique des Hôpitaux de Paris (AP-HP), Hôpital Henri-Mondor, Créteil, France.
| | - Askour Majda
- Dermatology Department, Assistance Publique des Hôpitaux de Paris (AP-HP), Hôpital Henri-Mondor, Créteil, France
| | - Charlotte Gary
- Dermatology Department, Assistance Publique des Hôpitaux de Paris (AP-HP), Hôpital Henri-Mondor, Créteil, France
| | - Francois Hemery
- Service d'Information Médicale, DSIGHM, APHP, Hôpital Henri-Mondor, Créteil, France
| | - Emmanuel Mahé
- Dermatology Department, Centre Hospitalier Victor Dupouy, Argenteuil, France
| | - Frederic Caux
- Dermatology Department, APHP, Hôpital Avicenne, Bobigny, France
| | - Nicolas Dupin
- Dermatology Department, APHP, Hôpital Cochin, Pavillon Tarnier, Paris, France
| | - Patricia Senet
- Dermatology Department, APHP, Hôpital Tenon, Sorbonne Université, Paris, France
| | - Alix Greder-Belan
- Service de Médecine Interne et Unité de Maladies Infectieuses et Tropicales, Centre Hospitalier de Versailles, Hôpital Mignot, Le Chesnay, France
| | - Brigitte Hillion
- Dermatology Department, Centre Hospitalier Marne la Vallée, Jossigny, France
| | - Cecile Meni
- Dermatology Department, APHP, Hôpital Necker-Enfants malades, Paris, France
| | - Philippe Saiag
- Dermatology Department, APHP, Hôpital Ambroise Paré, Boulogne-Billancourt, France
| | - Guillaume Bellaud
- Infectious Diseases Department, APHP, Hôpital Tenon, Hôpitaux Universitaires Paris-Est, Paris, France
| | - Alexandre Bleibtreu
- Infectious Diseases Department, APHP, Hôpital Bichat Claude Bernard, Paris, France
| | - Sylvie Lariven
- Infectious Diseases Department, APHP, Hôpital Bichat Claude Bernard, Paris, France
| | - Diane Bollens
- Infectious Diseases Department, APHP, Hôpital Saint-Antoine, Paris, France
| | - Vincent Descamps
- Dermatology Department, APHP, Hôpital Bichat Claude Bernard, Paris, France
| | - Jean-Michel Molina
- Infectious Diseases Department, APHP, Hôpital Saint-Louis, Paris, France
| | - Olivier Bouchaud
- Infectious Diseases Department, APHP, Hôpital Avicenne, Bobigny, France
| | - Daniel Vittecoq
- Infectious Diseases Department, APHP, CHU Bicêtre, Le Kremlin Bicêtre, France
| | - Gia Do-Pham
- Service de Médecine Interne, Centre Hospitalier Intercommunal de Créteil, Créteil, France
| | - Francoise Foulet
- Research Group Dynamic, EA7380, Faculté de Santé de Créteil, Ecole Nationale Vétérinaire d'Alfort, USC ANSES, Université Paris-Est Créteil, Créteil, France
| | - Francoise Botterel
- Research Group Dynamic, EA7380, Faculté de Santé de Créteil, Ecole Nationale Vétérinaire d'Alfort, USC ANSES, Université Paris-Est Créteil, Créteil, France
| | - Olivier Chosidow
- Dermatology Department, Assistance Publique des Hôpitaux de Paris (AP-HP), Hôpital Henri-Mondor, Créteil, France
| | - Charlotte Bernigaud
- Dermatology Department, Assistance Publique des Hôpitaux de Paris (AP-HP), Hôpital Henri-Mondor, Créteil, France.
| |
Collapse
|
11
|
Bertin C, Beaumont AL, Merlant M, Mailhe M, Le Pluart D, Deconinck L, Thy M, Cortier M, Garé M, Dollat M, Rahi M, Joly V, Lariven S, Rioux C, Truong A, Deschamps L, Ferré VM, Charpentier C, Lescure FX, Bouscarat F, Descamps V, Yazdanpanah Y, Peiffer-Smadja N. Erythematous maculopapular rash in monkeypox virus infection: A retrospective case series of 30 patients. J Eur Acad Dermatol Venereol 2023; 37:e638-e641. [PMID: 36648134 DOI: 10.1111/jdv.18876] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/16/2022] [Accepted: 01/09/2023] [Indexed: 01/18/2023]
Affiliation(s)
- Chloé Bertin
- Department of Infectious and Tropical Diseases, Bichat, Assistance Publique - Hôpitaux de Paris - Claude-Bernard University Hospital, Université Paris Cité, Paris, France
| | - Anne-Lise Beaumont
- Department of Infectious and Tropical Diseases, Bichat, Assistance Publique - Hôpitaux de Paris - Claude-Bernard University Hospital, Université Paris Cité, Paris, France
| | - Marie Merlant
- Service de Dermatologie, AP-HP, Hôpital Bichat-Claude Bernard, Paris, France
| | - Morgane Mailhe
- Department of Infectious and Tropical Diseases, Bichat, Assistance Publique - Hôpitaux de Paris - Claude-Bernard University Hospital, Université Paris Cité, Paris, France
| | - Diane Le Pluart
- Department of Infectious and Tropical Diseases, Bichat, Assistance Publique - Hôpitaux de Paris - Claude-Bernard University Hospital, Université Paris Cité, Paris, France
| | - Laurène Deconinck
- Department of Infectious and Tropical Diseases, Bichat, Assistance Publique - Hôpitaux de Paris - Claude-Bernard University Hospital, Université Paris Cité, Paris, France
| | - Michael Thy
- Department of Infectious and Tropical Diseases, Bichat, Assistance Publique - Hôpitaux de Paris - Claude-Bernard University Hospital, Université Paris Cité, Paris, France
| | - Marie Cortier
- Department of Infectious and Tropical Diseases, Bichat, Assistance Publique - Hôpitaux de Paris - Claude-Bernard University Hospital, Université Paris Cité, Paris, France
| | - Mathilde Garé
- Department of Infectious and Tropical Diseases, Bichat, Assistance Publique - Hôpitaux de Paris - Claude-Bernard University Hospital, Université Paris Cité, Paris, France
| | - Marion Dollat
- Department of Infectious and Tropical Diseases, Bichat, Assistance Publique - Hôpitaux de Paris - Claude-Bernard University Hospital, Université Paris Cité, Paris, France
| | - Mayda Rahi
- Department of Infectious and Tropical Diseases, Bichat, Assistance Publique - Hôpitaux de Paris - Claude-Bernard University Hospital, Université Paris Cité, Paris, France
| | - Véronique Joly
- Department of Infectious and Tropical Diseases, Bichat, Assistance Publique - Hôpitaux de Paris - Claude-Bernard University Hospital, Université Paris Cité, Paris, France
| | - Sylvie Lariven
- Department of Infectious and Tropical Diseases, Bichat, Assistance Publique - Hôpitaux de Paris - Claude-Bernard University Hospital, Université Paris Cité, Paris, France
| | - Christophe Rioux
- Department of Infectious and Tropical Diseases, Bichat, Assistance Publique - Hôpitaux de Paris - Claude-Bernard University Hospital, Université Paris Cité, Paris, France
| | - Audrey Truong
- Service d'anatomopathologie, AP-HP, Hôpital Bichat-Claude Bernard, Paris, France
| | - Lydia Deschamps
- Service d'anatomopathologie, AP-HP, Hôpital Bichat-Claude Bernard, Paris, France
| | - Valentine Marie Ferré
- Service de Virologie, INSERM, IAME, UMR 1137, AP-HP, Hôpital Bichat Claude Bernard, Université Paris Cité, Paris, France
| | - Charlotte Charpentier
- Service de Virologie, INSERM, IAME, UMR 1137, AP-HP, Hôpital Bichat Claude Bernard, Université Paris Cité, Paris, France
| | - François-Xavier Lescure
- Department of Infectious and Tropical Diseases, Bichat, Assistance Publique - Hôpitaux de Paris - Claude-Bernard University Hospital, Université Paris Cité, Paris, France
| | - Fabrice Bouscarat
- Service de Dermatologie, AP-HP, Hôpital Bichat-Claude Bernard, Paris, France
| | - Vincent Descamps
- Service de Dermatologie, AP-HP, Hôpital Bichat-Claude Bernard, Paris, France
| | - Yazdan Yazdanpanah
- Department of Infectious and Tropical Diseases, Bichat, Assistance Publique - Hôpitaux de Paris - Claude-Bernard University Hospital, Université Paris Cité, Paris, France
| | - Nathan Peiffer-Smadja
- Department of Infectious and Tropical Diseases, Bichat, Assistance Publique - Hôpitaux de Paris - Claude-Bernard University Hospital, Université Paris Cité, Paris, France
| |
Collapse
|
12
|
Colboc H, Bazin D, Reguer S, Lucas IT, Moguelet P, Amode R, Jouanneau C, Soria A, Chasset F, Amsler E, Pecquet C, Aractingi S, Bellot-Gurlet L, Deschamps L, Descamps V, Kluger N. Chemical characterization of inks in skin reactions to tattoo. J Synchrotron Radiat 2022; 29:1436-1445. [PMID: 36345752 PMCID: PMC9641572 DOI: 10.1107/s1600577522008165] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 02/07/2022] [Accepted: 08/15/2022] [Indexed: 06/16/2023]
Abstract
Skin reactions are well described complications of tattooing, usually provoked by red inks. Chemical characterizations of these inks are usually based on limited subjects and techniques. This study aimed to determine the organic and inorganic composition of inks using X-ray fluorescence spectroscopy (XRF), X-ray absorption spectroscopy (XANES) and Raman spectroscopy, in a cohort of patients with cutaneous hypersensitivity reactions to tattoo. A retrospective multicenter study was performed, including 15 patients diagnosed with skin reactions to tattoos. Almost half of these patients developed skin reactions on black inks. XRF identified known allergenic metals - titanium, chromium, manganese, nickel and copper - in almost all cases. XANES spectroscopy distinguished zinc and iron present in ink from these elements in endogenous biomolecules. Raman spectroscopy showed the presence of both reported (azo pigments, quinacridone) and unreported (carbon black, phtalocyanine) putative organic sensitizer compounds, and also defined the phase in which Ti was engaged. To the best of the authors' knowledge, this paper reports the largest cohort of skin hypersensitivity reactions analyzed by multiple complementary techniques. With almost half the patients presenting skin reaction on black tattoo, the study suggests that black modern inks should also be considered to provoke skin reactions, probably because of the common association of carbon black with potential allergenic metals within these inks. Analysis of more skin reactions to tattoos is needed to identify the relevant chemical compounds and help render tattoo ink composition safer.
Collapse
Affiliation(s)
- Hester Colboc
- Sorbonne Université, Hôpital Rothschild, Service de Gériatrie-Plaies et Cicatrisation, Paris, France
- Sorbonne Université, UPMC Paris 06, Institut National de la Santé et de la Recherche Médicale, Unité Mixte de Recherche S 1155, F-75020 Paris, France
| | - Dominique Bazin
- Institut de Chimie Physique, Université Paris-Saclay, Orsay, France
| | - Solenn Reguer
- DiffAbs Beamline, Synchrotron SOLEIL, L’Orme des Merisiers, Départementale 128, 91190 Saint-Aubin, France
| | - Ivan T. Lucas
- Sorbonne Université, CNRS, Laboratoire Lise UMR 8235, Paris, France
| | - Philippe Moguelet
- Sorbonne Université, Hôpital Tenon, Anatomie et Cytologie Pathologiques, Paris, France
| | | | - Chantal Jouanneau
- Sorbonne Université, UPMC Paris 06, Institut National de la Santé et de la Recherche Médicale, Unité Mixte de Recherche S 1155, F-75020 Paris, France
| | - Angèle Soria
- Sorbonne Université, Hôpital Tenon, Service de Dermatologie-Allergologie, Paris, France
| | - François Chasset
- Sorbonne Université, Hôpital Tenon, Service de Dermatologie-Allergologie, Paris, France
| | - Emmanuelle Amsler
- Sorbonne Université, Hôpital Tenon, Service de Dermatologie-Allergologie, Paris, France
| | - Catherine Pecquet
- Sorbonne Université, Hôpital Tenon, Service de Dermatologie-Allergologie, Paris, France
| | - Sélim Aractingi
- Université de Paris, Hôpital Cochin, Service de Dermatologie, Paris, France
| | | | - Lydia Deschamps
- Université de Paris, Hôpital Bichat, Service d’Anatomie et Cytologie Pathologique, Paris, France
| | - Vincent Descamps
- Université de Paris, Hôpital Bichat, Service de Dermatologie, Paris, France
| | - Nicolas Kluger
- Université de Paris, Hôpital Bichat, Service de Dermatologie, Paris, France
- Department of Dermatology, Allergology and Venereology, Helsinki University Hospital and University of Helsinki, Helsinki, Finland
| |
Collapse
|
13
|
Demouche S, Juge P, Charles P, Descamps V, Benali K, Brunet‐Possenti F. Safe use of tocilizumab in rheumatic patients with Kaposi's sarcoma. Dermatol Ther 2022; 35:e15797. [PMID: 36038806 PMCID: PMC9786762 DOI: 10.1111/dth.15797] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/22/2022] [Revised: 07/05/2022] [Accepted: 08/27/2022] [Indexed: 12/30/2022]
Affiliation(s)
- Sarah Demouche
- Department of DermatologyHôpital Bichat, AP‐HPParisFrance
| | - Pierre‐Antoine Juge
- Department of RheumatologyHôpital Bichat, AP‐HP, Université de ParisParisFrance
| | - Pierre Charles
- Department of Internal MedicineInstitut Mutualiste Montsouris, Université de ParisParisFrance
| | | | - Khadija Benali
- Department of Nuclear MedicineHôpital Bichat, AP‐HP, Université de ParisParisFrance
| | | |
Collapse
|
14
|
Colboc H, Moguelet P, Letavernier E, Frochot V, Bernaudin JF, Weil R, Rouzière S, Senet P, Bachmeyer C, Laporte N, Lucas I, Descamps V, Amode R, Brunet-Possenti F, Kluger N, Deschamps L, Dubois A, Reguer S, Somogyi A, Medjoubi K, Refregiers M, Daudon M, Bazin D. Pathologies related to abnormal deposits in dermatology: a physico-chemical approach. CR CHIM 2022. [DOI: 10.5802/crchim.153] [Citation(s) in RCA: 7] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
|
15
|
Affiliation(s)
- Vincent Descamps
- Department of Dermatology, Bichat Claude Bernard Hospital, APHP, Paris Cité University, Paris 75018, France.
| |
Collapse
|
16
|
Beydon M, Nicaise-Roland P, Mageau A, Farkh C, Daugas E, Descamps V, Dieude P, Dossier A, Goulenok T, Farhi F, Mutuon P, Timsit JF, Papo T, Sacre K. Autoantibodies against IFNα in patients with systemic lupus erythematosus and susceptibility for infection: a retrospective case-control study. Sci Rep 2022; 12:11244. [PMID: 35788140 PMCID: PMC9253327 DOI: 10.1038/s41598-022-15508-9] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/25/2022] [Accepted: 06/24/2022] [Indexed: 11/25/2022] Open
Abstract
IFNα and anti-IFNα autoantibodies have been implicated in susceptibility both for systemic lupus erythematosus (SLE) and viral infection. We aimed to analyze the SLE disease phenotype and risk for infection associated with anti-IFN-α IgG autoantibodies in SLE patients In this multidisciplinary retrospective single referral center study, all consecutive patients with SLE admitted between January 1st and November 30th 2020 were considered. All subjects fulfilled the ACR/EULAR 2019 criteria for SLE. Anti-IFNα IgG autoantibodies were quantified at admission by ELISA. Demographic, medical history, laboratory, treatment, and outcome data were extracted from electronic medical records using a standardized data collection form. 180 patients [female 87.2%, median age of 44.4 (34-54.2) years] were included. The median disease duration was 10 years [4-20] with a median SLEDAI score of 2 [0-4] at study time. Fifty-four (30%) patients had a past-history of lupus nephritis. One hundred and forty-four (80%) had received long-term glucocorticoids and 99 (55%) immunosuppressive drugs. Overall, 127 infections-mostly bacterial and viral-were reported in 95 (52.8%) patients. Twenty SLE patients (11.1%) had positive anti-IFNα IgG autoantibodies with a titer ranging from 10 to 103 UA/mL. Age, sex, SLE phenotype and treatment did not significantly differ between SLE patients with or without anti-IFNα. Infection rate was similar in both groups except for tuberculosis which was more frequent in patients with anti-IFNα (20% vs. 3.1%, p = 0.01). The prevalence of autoantibodies against IFNα is high in SLE and associated with a higher frequency of tuberculosis.
Collapse
Affiliation(s)
- Maxime Beydon
- Service de Médecine Interne, Hôpital Bichat, Assistance Publique Hôpitaux de Paris, 46 rue Henri Huchard, 75018, Paris, France
| | - Pascale Nicaise-Roland
- Service d'Immunologie « Autoimmunité, Hypersensibilités et Biothérapies », Hôpital Bichat, Assistance Publique Hôpitaux de Paris, Paris, France
- INSERM UMR1152, Université de Paris, Paris, France
| | - Arthur Mageau
- Service de Médecine Interne, Hôpital Bichat, Assistance Publique Hôpitaux de Paris, 46 rue Henri Huchard, 75018, Paris, France
- Laboratoire d'Excellence Inflamex, Faculté de Médecine Site Bichat, Centre de Recherche Sur L'Inflammation, INSERM UMR1149, CNRS ERL8252, Université de Paris, Paris, France
- IAME UMR1137, Equipe DeScID, Université de Paris, Paris, France
| | - Carine Farkh
- Service d'Immunologie « Autoimmunité, Hypersensibilités et Biothérapies », Hôpital Bichat, Assistance Publique Hôpitaux de Paris, Paris, France
| | - Eric Daugas
- Laboratoire d'Excellence Inflamex, Faculté de Médecine Site Bichat, Centre de Recherche Sur L'Inflammation, INSERM UMR1149, CNRS ERL8252, Université de Paris, Paris, France
- Département de Néphrologie, Hôpital Bichat, Assistance Publique Hôpitaux de Paris, Paris, France
| | - Vincent Descamps
- Département de Dermatologie, Hôpital Bichat, Assistance Publique Hôpitaux de Paris, Paris, France
| | - Philippe Dieude
- Département de Rhumatologie, Hôpital Bichat, Assistance Publique Hôpitaux de Paris, Paris, France
| | - Antoine Dossier
- Service de Médecine Interne, Hôpital Bichat, Assistance Publique Hôpitaux de Paris, 46 rue Henri Huchard, 75018, Paris, France
| | - Tiphaine Goulenok
- Service de Médecine Interne, Hôpital Bichat, Assistance Publique Hôpitaux de Paris, 46 rue Henri Huchard, 75018, Paris, France
| | - Fatima Farhi
- Service de Médecine Interne, Hôpital Bichat, Assistance Publique Hôpitaux de Paris, 46 rue Henri Huchard, 75018, Paris, France
| | - Pierre Mutuon
- Département d'Information Médicale, Hôpital Bichat, Assistance Publique Hôpitaux de Paris, Paris, France
| | - Jean-Francois Timsit
- IAME UMR1137, Equipe DeScID, Université de Paris, Paris, France
- Département de Réanimation Médicale Et Infectieuse, Hôpital Bichat, Assistance Publique Hôpitaux de Paris, Paris, France
| | - Thomas Papo
- Service de Médecine Interne, Hôpital Bichat, Assistance Publique Hôpitaux de Paris, 46 rue Henri Huchard, 75018, Paris, France
- Laboratoire d'Excellence Inflamex, Faculté de Médecine Site Bichat, Centre de Recherche Sur L'Inflammation, INSERM UMR1149, CNRS ERL8252, Université de Paris, Paris, France
| | - Karim Sacre
- Service de Médecine Interne, Hôpital Bichat, Assistance Publique Hôpitaux de Paris, 46 rue Henri Huchard, 75018, Paris, France.
- Laboratoire d'Excellence Inflamex, Faculté de Médecine Site Bichat, Centre de Recherche Sur L'Inflammation, INSERM UMR1149, CNRS ERL8252, Université de Paris, Paris, France.
| |
Collapse
|
17
|
Rousset P, Dalle S, Mortier L, Dereure O, Dalac S, Dutriaux C, Leccia MT, Legoupil D, Descamps V, De Quatrebarbes J, Grob JJ, Saiag P, Maubec E, Stoebner PE, Granel Brocard F, Arnault JP, Allayous C, Oriano B, Lebbe C, Montaudie H. Efficacy and tolerance of systemic therapies in metastatic melanoma of unknown primary versus known cutaneous: A multicenter retrospective study from the MelBase French Cohort. J Clin Oncol 2022. [DOI: 10.1200/jco.2022.40.16_suppl.9556] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
9556 Background: Melanoma of unknown primary (MUP) account for 3% of all melanomas. Clinical outcome of advanced MUP in the era of novel therapies including immunotherapies (ICI) and targeted therapies (TT) have been only scarcely studied, whereas a possibly different biologic background might introduce changes in its management. Recent retrospective studies suggested that patients with advanced MUP could benefit at least as much from novel therapies as patients with known primary cutaneous melanoma (cMKP). Methods: Based on the nationwide MelBase prospective database (NCT02828202) this retrospective study included patients with advanced melanoma treated with first-line ICI, TT or CT. MUP was defined by upfront occurrence of (sub)cutaneous, nodal and/or visceral metastasis without any known prior or concomitant primary tumor. Patients with primary mucosal or ocular melanoma were excluded. Both progression-free survival (PFS) and overall survival (OS) were analyzed as co-primary variables in MUP vs cMKP, stratified by treatment subset (ICI vs TT vs CT vs whole cohort). Secondary variable was treatment-related toxicity. Multivariate analyses and propensity score analysis were performed. Objective: To investigate the efficacy and safety of systemic treatments (ICI, TT and chemotherapy (CT)) in patients with advanced MUP comparatively to stage-matched cMKP. Results: A total of 1882 patients were analyzed, including 265 (14.1%) MUP. Most patients were treated with first-line ICI. Median follow-up was 16 months. Patients in the MUP cohort more often displayed unfavorable initial prognostic factors (Table). PFS and OS did not significantly differ in MUP compared to MKP patients (p=0.73 and p=0.93 respectively). Stratification of cohorts by treatment type and application of propensity score did not lead to data modification. Treatment-related toxicity rate and severity did not differ between MUP and MKP, regardless of treatment type. Conclusions: Our results suggest that advanced MUP should be managed with similar strategies as advanced MKP. In our cohort, MUP patients benefited from novel therapies as much as MKP patients despite less favorable baseline prognostic factors. Exploratory studies investigating mutational burden and host immunity are needed to identify the underlying mechanisms. [Table: see text]
Collapse
Affiliation(s)
| | - Stéphane Dalle
- Unit of Dermatology, Hospices Civils de Lyon, Cancer Research Center of Lyon, Pierre-Bénite, France
| | - Laurent Mortier
- Universite Lille, Centre Hospitalier Regional Universitaire de Lille, Lille, France
| | - Olivier Dereure
- Dermatology Department, Universitary Hospital of Montpellier, Montpellier, France
| | | | - Caroline Dutriaux
- Centre Hospitalier Universitaire de Bordeaux, Hôpital Saint-André, Bordeaux, France
| | - Marie Thérèse Leccia
- Dermatology Department, CHU Albert Michalon, Grenoble; Université de Grenoble, Grenoble, France
| | | | | | | | | | - Philippe Saiag
- Dermatology Department, Ambroise Paré Hospital, APHP, Versailles University – Paris-Saclay, Boulogne-Billancourt, France
| | | | | | | | | | - Clara Allayous
- AP-HP Hôpital Saint-Louis Dermatology Department, Paris, France
| | - Bastien Oriano
- Biostatistics, Department of Dermatology, Paris University Saint-Louis Hospital, Paris, France
| | - Celeste Lebbe
- Universite de Paris, AP-HP Hôpital Saint-Louis, Dermatology Department, Paris, France
| | | |
Collapse
|
18
|
Beydon M, Nicaise Roland P, Mageau A, Goulenok T, Farkh C, Dieudé P, Daugas E, Descamps V, Timsit JF, Papo T, Sacre K. AB0449 THE PREVALENCE OF AUTOANTIBODIES AGAINST IFNΑ IS HIGH IN SLE AND ASSOCIATED WITH A HIGH FREQUENCY OF TUBERCULOSIS. Ann Rheum Dis 2022. [DOI: 10.1136/annrheumdis-2022-eular.16] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
BackgroundIFNα and anti-IFNα autoantibodies have been implicated in susceptibility both for systemic lupus erythematosus (SLE) and viral infection.ObjectivesWe aimed to analyze the SLE disease phenotype and risk for infection associated with anti-IFN-α IgG autoantibodies in SLE patientsMethodsIn this multidisciplinary retrospective single referral center study, all consecutive patients with SLE admitted between January 1st and November 30th 2020 were considered. All subjects fulfilled the ACR/EULAR 2019 criteria for SLE. Anti-IFNα IgG autoantibodies were quantified at admission by ELISA. Demographic, medical history, laboratory, treatment, and outcome data were extracted from electronic medical records using a standardized data collection form.Results180 patients [female 87.2%, median age of 44.4 (34-54.2) years] were included. The median disease duration was 10 years [4-20] with a median SLEDAI score of 2 [0-4] at study time. Fifty-four (30%) patients had a past-history of lupus nephritis. One hundred and forty-four (80%) had received long-term glucocorticoids and 99 (55%) immunosuppressive drugs. Overall, 127 infections - mostly bacterial and viral - were reported in 95 (52.8%) patients. Twenty SLE patients (11.1%) had positive anti-IFNα IgG autoantibodies with a titer ranging from 10 to 103 UA/mL. Age, sex, SLE phenotype and treatment did not significantly differ between SLE patients with or without anti-IFNα. Infection rate was similar in both groups except for tuberculosis which was more frequent in patients with anti-IFNα (20% vs 3.1%, p = 0.01).ConclusionThe prevalence of autoantibodies against IFNα is high in SLE and associated with a higher frequency of tuberculosisDisclosure of InterestsNone declared
Collapse
|
19
|
Weill A, Descamps V, Chasset F, Mahévas T, Bourgault-Villada I, Wolkenstein P, Chollet-Martin S, Ingen-Housz-Oro S, Grootenboer-Mignot S. Erythema multiforme associated with anti-plakin antibodies: a multicentric retrospective case series. J Eur Acad Dermatol Venereol 2022; 36:2438-2442. [PMID: 35607912 DOI: 10.1111/jdv.18259] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/07/2021] [Accepted: 05/05/2022] [Indexed: 11/28/2022]
Abstract
BACKGROUND Erythema multiforme (EM) is a muco-cutaneous inflammatory disease mainly triggered by herpes simplex virus (HSV) recurrences. Association of EM and circulating auto-antibodies against plakins (anti-PLK-Abs [EM-PLK+]) has been reported. However, little is known about this subset of EM. OBJECTIVES We aimed to describe the clinical and immunological features and response to treatment of EM-PLK+. METHODS We conducted a retrospective multicentric study of EM-PLK+ selected from the database of the immunological laboratory of Bichat hospital, Paris, France, from January 2009 to December 2020. Anti-PLK-Abs were detected in ≥1 immunological tests: immunofluorescence assay, immunoblotting and/or ELISA. Patients with alternative diagnoses were excluded. RESULTS We included 29 patients (16 women, median age 25 [range 2-58] years). EM-PLK+ were mostly major (EM with ≥2 mucosal involvements; n = 24, 83%) and relapsing (≥2 flares; n = 23, 79%). Cutaneous lesions were target (n = 13, 54%) and target-like lesions (n = 9, 38%) with usual topography (acral, n = 19, 79%; limbs, n = 21, 88%). Mucosal lesions affected the mouth (n = 27, 96%) and genitalia (n = 19, 68%), with a median of 2 [range 0-5] mucous membranes. EM-PLK+ were suspected as certain or possible postherpetic (EM-HSV) in 19 cases (65.5%); no triggering factors were detected in 9 (31%) patients. Desmoplakin-I/II Abs were the most frequent anti-PLK-Abs (n = 20, 69%); envoplakin and periplakin Abs were detected in 11 and 9 cases. Relapsing EM-PLK+ (n = 23) were still active (≥1 flare within 6 months) in 13 (57%) patients despite immunosuppressive therapy (n = 8, 62%). Antiviral drugs were ineffective in preventing relapse in 15/16 (94%) EM-HSV. CONCLUSION The rationale for anti-PLK-Ab detection in EM is not elucidated. More systematic research of anti-PLK-Abs is warranted to better understand whether this association reflects humoral immune activity in a subset of EM or is fortuitous, related to an epitope spreading process. However, EM-PLK+ seems to be associated with major and relapsing subtypes, and difficult-to-treat cases.
Collapse
Affiliation(s)
- A Weill
- Department of Dermatology, CHU Henri Mondor, AP-HP, Créteil, France.,Referral Center for Toxic Bullous Dermatoses and Severe Drug Reactions TOXIBUL, Créteil, France.,Referral Center for Auto-Immune Bullous Diseases (MALIBUL), AP-HP, Paris, France
| | - V Descamps
- Department of Dermatology, CHU Bichat, AP-HP, Paris, France
| | - F Chasset
- Faculty of Medicine, Department of Dermatology, CHU Tenon, AP-HP, Sorbonne Université, Paris, France
| | - T Mahévas
- Department of Dermatology, CHU Saint-Louis, AP-HP, Paris, France
| | - I Bourgault-Villada
- Department of Dermatology, CHU Ambroise Paré, AP-HP, Boulogne Billancourt, France
| | - P Wolkenstein
- Department of Dermatology, CHU Henri Mondor, AP-HP, Créteil, France.,Referral Center for Toxic Bullous Dermatoses and Severe Drug Reactions TOXIBUL, Créteil, France.,Referral Center for Auto-Immune Bullous Diseases (MALIBUL), AP-HP, Paris, France.,Univ Paris Est Créteil Epiderm E, Créteil, France
| | | | - S Ingen-Housz-Oro
- Department of Dermatology, CHU Henri Mondor, AP-HP, Créteil, France.,Referral Center for Toxic Bullous Dermatoses and Severe Drug Reactions TOXIBUL, Créteil, France.,Referral Center for Auto-Immune Bullous Diseases (MALIBUL), AP-HP, Paris, France.,Univ Paris Est Créteil Epiderm E, Créteil, France
| | - S Grootenboer-Mignot
- Referral Center for Auto-Immune Bullous Diseases (MALIBUL), AP-HP, Paris, France.,Department of Immunobiology, CHU Bichat, AP-HP, Paris, France
| |
Collapse
|
20
|
Kluger N, Descamps V. Efficacy of low‐dose methotrexate in a short‐regimen for granulomatous sarcoid‐like reaction on permanent make‐up during COVID‐19 infection. J Eur Acad Dermatol Venereol 2022; 36:e741-e742. [PMID: 35604051 PMCID: PMC9348066 DOI: 10.1111/jdv.18252] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/01/2022] [Accepted: 05/18/2022] [Indexed: 11/29/2022]
Affiliation(s)
- Nicolas Kluger
- « Tattoo consultation », Department of Dermatology, Bichat‐Claude Bernard Hospital, Assistance Publique‐Hôpitaux de Paris Paris France
- Department of Dermatology, Allergology, and Venereology University of Helsinki and Helsinki University Hospital Helsinki Finland
| | - Vincent Descamps
- « Tattoo consultation », Department of Dermatology, Bichat‐Claude Bernard Hospital, Assistance Publique‐Hôpitaux de Paris Paris France
| |
Collapse
|
21
|
Richette P, Allez M, Descamps V, Perray L, Pilet S, Latourte A, Maravic M. Impact de la COVID-19 sur l’initiation des prescriptions des biothérapies dans les maladies inflammatoires chroniques. Revue du Rhumatisme 2022; 89:313-314. [PMID: 34697532 PMCID: PMC8529531 DOI: 10.1016/j.rhum.2021.10.560] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Accepted: 07/13/2021] [Indexed: 12/01/2022]
Affiliation(s)
- Pascal Richette
- Rheumatology department, Lariboisière Hospital, AP-HP, Paris, France
- Inserm U1132, Paris University, Paris, France
| | - Matthieu Allez
- Gastro Enterology department, St-Louis Hospital, AP-HP, Paris, France
| | | | | | | | - Augustin Latourte
- Rheumatology department, Lariboisière Hospital, AP-HP, Paris, France
- Inserm U1132, Paris University, Paris, France
| | | |
Collapse
|
22
|
Mariette C, Lavaud J, Descamps V. Stress induced by messenger ribonucleic acid (RNA) vaccination may reveal acute adrenal insufficiency. Endocrine 2022; 75:659-660. [PMID: 34545511 PMCID: PMC8452120 DOI: 10.1007/s12020-021-02878-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/05/2021] [Accepted: 09/11/2021] [Indexed: 10/29/2022]
|
23
|
Dauchez A, Dumas-Lattaque M, Deschamps L, Lavaud J, Lheure C, Brunet-Possenti F, Descamps V. [Cutaneous manifestation of lymphoid variant of hypereosinophilic syndrome: One case]. Rev Med Interne 2022; 43:256-259. [PMID: 35034806 DOI: 10.1016/j.revmed.2021.12.007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/02/2021] [Revised: 11/11/2021] [Accepted: 12/23/2021] [Indexed: 11/18/2022]
Abstract
INTRODUCTION Lymphoid hypereosinophilic syndrome (HES) is a reactive HES, related to the presence of an abnormal circulating T cell clone. Cutaneous manifestations are frequent and sometimes inaugural, however few studies describe them specifically. CASE REPORT We report the case of a 63-year old patient, in good general condition, with no previous history and taking no treatment, who was being followed for non-specific skin lesions. Blood and skin examinations showed hypereosinophilia, the presence of an aberrant CD3-CD4+ phenotype and a positive T-clonality test. There was no differential diagnosis or argument for a systemic lymphoma. CONCLUSION Cutaneous manifestations of lymphoid HES are variable, non-specific, and may differ according to lymphocyte phenotype. The discovery of SHE requires an extension workup and the risk of evolution towards a systemic lymphoma justifies a close surveillance. Treatment is adapted to the severity of the symptoms.
Collapse
Affiliation(s)
- A Dauchez
- Service de dermatologie, hôpital Bichat, AP-HP, 46, rue Henri-Huchard, 75018 Paris, France.
| | - M Dumas-Lattaque
- Service de dermatologie, hôpital Bichat, AP-HP, 46, rue Henri-Huchard, 75018 Paris, France
| | - L Deschamps
- Service d'anatomopathologie, hôpital Bichat, AP-HP, 46, rue Henri-Huchard, 75018 Paris, France
| | - J Lavaud
- Service de dermatologie, hôpital Bichat, AP-HP, 46, rue Henri-Huchard, 75018 Paris, France
| | - C Lheure
- Service de dermatologie, hôpital Bichat, AP-HP, 46, rue Henri-Huchard, 75018 Paris, France
| | - F Brunet-Possenti
- Service de dermatologie, hôpital Bichat, AP-HP, 46, rue Henri-Huchard, 75018 Paris, France
| | - V Descamps
- Service de dermatologie, hôpital Bichat, AP-HP, 46, rue Henri-Huchard, 75018 Paris, France
| |
Collapse
|
24
|
Bedon M, Roland Nicaise P, Mageau A, Farkh C, Daugas E, Descamps V, Dieude P, Timsit J, Papo T, Sacré K. Risque infectieux et phénotype clinique associée aux auto-anticorps anti-IFNα dans le lupus érythémateux systémique (LES). Rev Med Interne 2021. [PMCID: PMC8610746 DOI: 10.1016/j.revmed.2021.10.223] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
25
|
Archimbaud J, Deschamps L, Descamps V, Brunet-Possenti F, Gillet B, Bouscarat F. Régression spontanée d’un carcinome épidermoïde invasif au décours d’une infection à COVID-19. Annales de Dermatologie et de Vénéréologie - FMC 2021. [PMCID: PMC8603680 DOI: 10.1016/j.fander.2021.09.107] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Download PDF] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
Abstract
Introduction L’utilisation de virus oncolytiques combinée à l’immunothérapie (tel que le T-VEC) est en passe de devenir une stratégie majeure en oncologie. Des régressions tumorales après infections virales sont possibles. Nous rapportons un cas de régression complète d’un carcinome épidermoïde invasif dans le contexte d’une infection par la COVID-19 avec signes généraux marqués. Matériel et méthodes Il s’agissait d’un patient de 75 ans en excellent état général ayant comme principal antécédent une polyarthrite rhumatoïde bien contrôlé sous méthotrexate depuis janvier 2020. En janvier 2021, apparaissait en 15 jours une lésion nodulaire de 1 cm, infiltrante et ulcérée sur la commissure labiale gauche. L’histologie a conclu à un carcinome épidermoïde infiltrant moyennement différencié non kératinisant avec en immunohistochimie une expression forte de CK5/6+, plus discrète et focale de la p40. Le méthotrexate était arrêté. Dans les 15 jours suivant la biopsie, la croissance tumorale a été très rapide (diamètre 2,5 cm). Le bilan d’extension mettait en évidence de multiples opacités du parenchyme pulmonaire gauche, des nodules hépatiques et une lésion pancréatique. La ponction biopsie hépatique objectivait une métastase d’un adénocarcinome de phénotype bilio-pancréatique (positivité CK19 et CK7+, négativité CK5/6 et p40). Après RCP une radiothérapie de ce carcinome épidermoïde très évolutif et une chimiothérapie par Folfirinox de l’adénocarcinome pancréatique ont été proposées. En raison d’une PCR SARS- Cov-2 positive le 26/03 ces deux traitements ont été différés. Le patient développait alors une infection symptomatique marquée par des signes généraux majeurs (fièvre, asthénie). Dans ce contexte on observait une régression complète du carcinome labial en 15 jours, confirmée histologiquement. Discussion La régression spontanée de carcinome épidermoïde à type de kératoacanthome (KA) est un phénomène décrit. La tumeur décrite ici ne répond pas aux critères de KA. L’hypothèse d’une réponse anti virale de type interféron (IFN) avec effet anti tumoral est évoquée. Une action oncolytique directe du SARS-CoV-2 (présent dans la sphère orolabiale) sur les cellules tumorales est possible. Cette observation est exemplaire d’un avenir possible de ces virus dans le domaine de l’oncologie. Une observation d’une rémission d’un lymphome NK/T associé à l’EBV a été récemment rapportée au cours d’une infection COVID-19. Ce virus présente en effet les caractéristiques idéales pour en faire un prochain vecteur oncolytique. Il a un haut niveau de réplication permettant une persistance virale prolongée, une capacité à infecter différents types cellulaires dont les cellules épithéliales et surtout d’induire une forte réponse immunitaire cellulaire.
Collapse
|
26
|
Roux C, Sbidian E, Bouaziz JD, Kottler D, Joly P, Descamps V, Prost C, Samimi M, Seneschal J, Dupin N, Girard C, Paul M, Le Cleach L, Ingen-Housz-Oro S. Evaluation of Thalidomide Treatment of Patients With Chronic Erythema Multiforme: A Multicenter Retrospective Cohort Study. JAMA Dermatol 2021; 157:1472-1476. [PMID: 34757396 DOI: 10.1001/jamadermatol.2021.4083] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
Abstract
Importance Erythema multiforme (EM) may become long term, with a recurrent or persistent course. First-line treatment for chronic EM is valaciclovir. There is no consensus for selection of second-line treatment of chronic EM. Objective The aim of this study was to assess the effectiveness of treatment with thalidomide for patients with chronic EM. Design, Setting, and Participants In this retrospective national multicenter cohort study, among 68 French hospital dermatology departments contacted by e-mail, 10 reported having eligible cases. All adults aged 18 years or older under dermatology care for chronic EM (including recurrent and persistent forms) who had received thalidomide between 2010 and 2018 were included. Analyses were conducted from June 24, 2019, to December 31, 2019. Main Outcomes and Measures The primary outcome was the proportion of patients who did not experience an EM flare within 6 months of initiating thalidomide treatment for recurrent EM or with complete clearance at 6 months for persistent EM (complete remission). Results Overall, 35 patients with chronic EM (median [range] age, 33 [15-65] years; 20 [57%] female) experienced failure of at least 1 previous treatment prior to initiating treatment with thalidomide. After 6 months of continuous thalidomide treatment, 23 (66%) were in complete remission, 5 (14%) had stopped the treatment, and 7 (20%) experienced at least 1 flare. The median (IQR) initial dose followed by remission was 50 (50-100) mg/d. Main adverse effects were asthenia (16 [46%]) and neuropathy (14 [40%]). Twenty-five (71%) of patients stopped thalidomide treatment after a median (IQR) of 12 (8-20) months owing to lack of effect (7/25 [28%]), neuropathy or another adverse effect (14/25 [56%]), or long-term complete remission (4/25 [16%]). Low-dose thalidomide, less than 50 mg every other day was sufficient in 9 of 23 (39%) of responders and was associated with less neuropathy and longer treatment duration. Conclusions and Relevance In this cohort study, second-line therapy with thalidomide was associated with complete remission in two-thirds of the 35 patients with chronic EM. However, adverse events were a common cause of thalidomide withdrawal. In the long term, dose reduction when possible may allow for continuation by improving tolerance.
Collapse
Affiliation(s)
- Camille Roux
- Department of Dermatology, Henri Mondor Hospital, AP-HP, Créteil, France
| | - Emilie Sbidian
- Department of Dermatology, Henri Mondor Hospital, AP-HP, Créteil, France.,Université Paris Est Créteil EpiDermE, Créteil, France
| | - Jean-David Bouaziz
- Department of Dermatology, Saint-Louis Hospital, AP-HP, Université de Paris, Paris, France
| | - Diane Kottler
- Department of Dermatology, Bichat Hospital, AP-HP, Université de Paris, Paris, France.,Department of Dermatology, Caen University Hospital, Caen, France
| | - Pascal Joly
- Department of Dermatology, Rouen University Hospital and INSERM 1234, Normandie University, Rouen, France
| | - Vincent Descamps
- Department of Dermatology, Bichat Hospital, AP-HP, Université de Paris, Paris, France.,Department of Dermatology, Caen University Hospital, Caen, France
| | - Catherine Prost
- Department of Dermatology, Avicenne Hospital, AP-HP, Bobigny, France
| | - Mahtab Samimi
- Department of Dermatology, University Hospital of Tours, Tours, France
| | - Julien Seneschal
- Department of Dermatology, National Reference Center for Rare Skin Diseases, Université Bordeaux, Bordeaux, France
| | - Nicolas Dupin
- Department of Dermatology, Cochin Hospital, AP-HP, Paris, France
| | - Céline Girard
- Department of Dermatology, Montpellier University Hospital, Montpellier, France
| | - Muriel Paul
- Université Paris Est Créteil EpiDermE, Créteil, France.,Department of Hospital Pharmacy, Henri Mondor Hospital, AP-HP, Créteil, France
| | - Laurence Le Cleach
- Department of Dermatology, Henri Mondor Hospital, AP-HP, Créteil, France.,Université Paris Est Créteil EpiDermE, Créteil, France
| | - Saskia Ingen-Housz-Oro
- Department of Dermatology, Henri Mondor Hospital, AP-HP, Créteil, France.,Université Paris Est Créteil EpiDermE, Créteil, France.,Reference Center for toxic bullous dermatoses and severe drug reactions TOXIBUL, Créteil, France
| |
Collapse
|
27
|
Chastagner M, Shourik J, Jachiet M, Battistella M, Lefevre G, Gibier JB, Aubert H, Musquer M, Descamps V, Deschamps L, Chosidow O, Ortonne N, Groh M, Bernier M, Jullien D, Chasset F, Staumont-Salle D, Bouaziz JD, Kanitakis J, Villani AP. Treatment of Eosinophilic Annular Erythema: Retrospective multicenter study and literature review. Ann Dermatol Venereol 2021; 149:123-127. [PMID: 34716028 DOI: 10.1016/j.annder.2021.07.007] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/12/2021] [Revised: 03/21/2021] [Accepted: 07/30/2021] [Indexed: 10/20/2022]
Abstract
BACKGROUND Eosinophilic annular erythema (EAE) is a rare eosinophil-related skin disease which typically manifests with annular erythematous plaques and severe pruritus. Besides the diagnosis, the treatment of EAE is challenging since relevant published data are sparse. METHODS The aim of this study was to assess the underlying diseases, treatments and outcomes of patients with EAE. To this end, we conducted a retrospective multicenter study and a systematic review of the MEDLINE database. RESULTS We included 18 patients with EAE followed in 8 centers. The MEDLINE database search yielded 37 relevant publications reporting 55 cases of EAE with 106 treatment sequences. The most common and efficient treatments included topical or systemic corticosteroids, hydroxychloroquine and dapsone. In refractory patients, a combination of systemic corticosteroids with hydroxychloroquine was associated with 88% of complete clinical response. DISCUSSION To improve the management of EAE patients, we discuss the following treatment strategy: in topical steroid-resistant patients, hydroxychloroquine can be given as first-line systemic treatment. Dapsone, hydroxychloroquine or systemic corticosteroids are second-line options to consider. Last, monoclonal antibodies or JAK inhibitors targeting type 2 inflammation could represent promising last-resort options in refractory patients.
Collapse
Affiliation(s)
- M Chastagner
- Department of Dermatology, CHU Lyon, Université Claude Bernard Lyon I, 69000 Lyon, France
| | - J Shourik
- Sorbonne université, Faculté de médecine, Service de Dermatologie et Allergologie, Hôpital Tenon, AP-HP, 75020 Paris, France
| | - M Jachiet
- Department of Dermatology, Hôpital Saint-Louis, AP-HP Université de Paris, 75010 Paris, France
| | - M Battistella
- Pathology Department, Hôpital Saint-Louis, AP-HP, Université de Paris, Inserm U976, 75010 Paris, France
| | - G Lefevre
- CEREO (National reference center for Hypereosinophilic Syndromes), 75010 Paris, France; Department of Internal Medicine, CHU Lille, 59000 Lille, France
| | - J-B Gibier
- Pathology Department, CHU Lille, 59000 Lille, France
| | - H Aubert
- Dermatology Department, CHU Nantes, 44000 Nantes, France
| | - M Musquer
- Pathology Department, CHU, 44000 Nantes, France
| | - V Descamps
- Dermatology Department, Hôpital Bichat, 75018 Paris, France
| | - L Deschamps
- Pathology Department, Hôpital Bichat, 75018 Paris, France
| | - O Chosidow
- Faculté de Santé de Créteil et Service de Dermatologie, APHP, Hôpital Henri-Mondor, Université Paris-Est, Créteil, France and Research Group Dynamic, EA7380, Faculté de Santé de Créteil, Ecole Nationale Vétérinaire d'Alfort, USC ANSES, Université Paris-Est Créteil, 94010 Créteil, France
| | - N Ortonne
- Pathology Department, Hôpital Mondor, CHU Créteil, 94010 Créteil, France
| | - M Groh
- CEREO (National reference center for Hypereosinophilic Syndromes), 75010 Paris, France; Department of Internal Medicine, Hôpital Foch, 92150 Suresnes, France
| | - M Bernier
- Pathology Department, Hôpital Foch, 92150 Suresnes, France
| | - D Jullien
- Department of Dermatology, CHU Lyon, Université Claude Bernard Lyon I, 69000 Lyon, France
| | - F Chasset
- Sorbonne université, Faculté de médecine, Service de Dermatologie et Allergologie, Hôpital Tenon, AP-HP, 75020 Paris, France
| | - D Staumont-Salle
- Department of Dermatology, CHU Lille, Inserm U1286 INFINITE (Institute for Translational Research in Inflammation), University Lille, 59000 Lille, France
| | - J-D Bouaziz
- Department of Dermatology, Hôpital Saint-Louis, AP-HP Université de Paris, 75010 Paris, France
| | - J Kanitakis
- Department of Dermatology, CHU Lyon, Université Claude Bernard Lyon I, 69000 Lyon, France
| | - A P Villani
- Department of Dermatology, CHU Lyon, Université Claude Bernard Lyon I, 69000 Lyon, France.
| |
Collapse
|
28
|
Common M, El Khalifa J, Beytout Q, Grootenboer-Mignot S, Deschamps L, Descamps V. Non-coeliac gluten sensitivity: an underdiagnosed condition in dermatology? J Eur Acad Dermatol Venereol 2021; 36:e102-e104. [PMID: 34487592 DOI: 10.1111/jdv.17642] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/18/2021] [Accepted: 09/02/2021] [Indexed: 11/26/2022]
Affiliation(s)
- M Common
- Dermatology Department, Bichat Claude Bernard University Hospital, Paris, France
| | - J El Khalifa
- Dermatology Department, Bichat Claude Bernard University Hospital, Paris, France
| | - Q Beytout
- Anatomopathology Department, Bichat Claude Bernard University Hospital, Paris, France
| | | | - L Deschamps
- Anatomopathology Department, Bichat Claude Bernard University Hospital, Paris, France
| | - V Descamps
- Dermatology Department, Bichat Claude Bernard University Hospital, Paris, France
| |
Collapse
|
29
|
Richette P, Allez M, Descamps V, Perray L, Pilet S, Latourte A, Maravic M. Impact of COVID-19 on initiation of biologic therapy prescriptions for chronic inflammatory diseases. Joint Bone Spine 2021; 89:105253. [PMID: 34314887 PMCID: PMC8305295 DOI: 10.1016/j.jbspin.2021.105253] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/18/2021] [Accepted: 07/13/2021] [Indexed: 12/03/2022]
Affiliation(s)
- Pascal Richette
- Rheumatology department, Lariboisière Hospital, AP-HP, 2, rue Ambroise Paré, 75010 Paris, France; Inserm U1132, Paris University, Paris, France.
| | - Matthieu Allez
- Gastro Enterology department, St-Louis Hospital, AP-HP, Paris, France
| | | | | | | | - Augustin Latourte
- Rheumatology department, Lariboisière Hospital, AP-HP, 2, rue Ambroise Paré, 75010 Paris, France; Inserm U1132, Paris University, Paris, France
| | | |
Collapse
|
30
|
Weill A, Brunet-Possenti F, Léonard-Louis S, Delyon J, Bonniaud B, Jeudy G, Descamps V, Dinulescu M, Le Corre Y, Psimaras D, Baroudjian B, Hervier B. Myopathies inflammatoires induites par les inhibiteurs de point de contrôle immunitaire : spectre clinique et traitements. Rev Med Interne 2021. [DOI: 10.1016/j.revmed.2021.03.239] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
31
|
Weill A, Le Corre Y, Brunet-Possenti F, Léonard-Louis S, Delyon J, Bonniaud B, Jeudy G, Descamps V, Dinulescu M, Psimaras D, Baroudjian B, Hervier B. Myopathies inflammatoires induites par les inhibiteurs de point de contrôle immunitaire : la reprise d’une immunothérapie est possible. Rev Med Interne 2021. [DOI: 10.1016/j.revmed.2021.03.240] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
32
|
Richette P, Allez M, Descamps V, Perra L, Pilet S, Maravic M. POS1237 ALGORITHM IDENTIFYING CHRONIC INFLAMMATORY DISEASES TREATED BY BIOTHERAPY AND/OR TARGETED SYNTHETIC TREATMENTS IN OUTPATIENT CARE IN FRANCE: FEASIBILITY, PRELIMINARY RESULTS, AND IMPACT OF COVID-19. Ann Rheum Dis 2021. [DOI: 10.1136/annrheumdis-2021-eular.3165] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
Background:Discriminating chronic inflammatory diseases under biotherapy and/or targeted synthetic treatments (B/TST) using medico-administrative databases are challenging but required for medico-economic analyses focusing on these diseases.Objectives:The objective was to evaluate the feasibility of using a medication dispense data in order to identify patients with chronic inflammatory diseases under B/TST in outpatient care setting and evaluate the impact of COVID-19 in FranceMethods:LRx contains all anonymized medication dispenses prescribed in outpatient care in a representative panel of French retails pharmacies, including data of near 40 million patients. Patients having at least one B/TST delivered in 2019 were selected. An algorithm was constructed using different steps, including a machine learning step by transfer learning applied in patient classified as having a rheumatologic condition in order to differentiate rheumatoid arthritis (RA) from spondyloarthritis (SA). We numbered 190,640 patients, of which 87.8% were classified in one of the following diseases: RA, SA, psoriatic arthritis (PA), psoriasis, inflammatory bowel diseases (IBD) (extrapolated data to France). Descriptive analysis was performed. The impact of COVID-19 on biotherapy initiation was evaluated during the lockdown period (W2-W19 2020) in these different conditions.Results:Among the 167,468 patients under B/TST, 20.7%, 18.4%, 6.5%, 37.9% and 16.5% were considered as having a psoriasis, IBD, PA, RA, and SA, respectively. Female patients were more frequent in RA and PA (> 60%); younger (< 20 years) and older patients (74 years) were found in patients with IBD (5.7%) and RA (12.6%), respectively. Contrasting with IBD, SA, and RA patients were mainly under anti-TNF treatment (> 90% for IBD and SA, 73.5% for RA), psoriasis and PA patients received a range of broadly well-balanced of B/TST. Among the immunosuppressant, methotrexate was mostly prescribed in RA (58.4%), PA (34.1%), and psoriasis (14.1%), and azathioprine in IBD (19.9%). Oral corticosteroid delivered at least 4 times in 2019 were mostly found to be associated with a RA condition (28%). A significant decrease of biotherapy initiation was observed during the lockdown in France in patients with IBD (-20%, p=0.03) and psoriasis (-54%, p<0.0001), not significant decrease in patients with SA (-6%) and increase in RA patients (+23%).Conclusion:The algorithm was able to identify patients with chronic inflammatory diseases under B/TST delivered in outpatient care and will allow to follow-up its management and study the COVID-19 impact on biotherapy initiation. An external validation needs to be performedDisclosure of Interests:None declared
Collapse
|
33
|
Richette P, Allez M, Descamps V, Perra L, Pilet S, Maravic M. POS1236 IMPACT OF COVID-19 ON INITIATION AND RENEWAL OF BIOTHERAPIES AND TARGETED SYNTHETIC TREATMENTS. Ann Rheum Dis 2021. [DOI: 10.1136/annrheumdis-2021-eular.3146] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
Background:During the epidemic’s peak of COVID-19, scientific societies published recommendations on biotherapy and targeted synthetic treatment (B/TST) use in patients with chronic articular inflammatory diseases, inflammatory bowel diseases, and psoriasis.Objectives:The objective was to evaluate the impact of COVID-19 in France on initiation and renewal of B/TST.Methods:LRx contains all anonymized medication dispenses prescribed in outpatient care in a representative panel of French retails pharmacies, including data of near 40 million patients. The impact of B/TST initiation and renewal were studied using 2019 as reference and dispense deliveries data of pharmacies with regular flew in order to perform the comparison. B/TST considered were abatacept, anti-TNF, anti-IL6, anti-IL17, anti-IL12/23 or anti-IL23, JAK inhibitors (JAKi) and other classes such as aprelimast, aminosalicylates (AS), hydroxychloroquine (HCQ), and methotrexate (MTX). A treatment initiated was defined as a treatment not delivered in the past 12 months, and conversely for a treatment renewal. Results were presented as raw one and expressed in percentage of patients having at least one B/TST delivery in each therapeutic classes of interest in 2020 compared to 2019 used as reference year (period from week 12 to week 19 considered and corresponding to the lockdown period in France).Results:During the lockdown period, a decrease in initiation was observed for patients treated with: abatacept (405 in 2019 vs 227 in 2020: -44%, p<0.001), anti-TNF (1156 vs 1058, -31%, p<0.001), anti-IL17 (415 vs 206, -50%, p<0.001), anti-IL12-23 (395 vs 339, -12%, p=0.16), JAKi (289 vs 174, -39%, p=0.006), contrasting with an increase for Tociliumab (117 vs 445, +152%, p=0,01). We found a decrease of 7% (2171 vs 2015, p=0,35), 44% (405 vs 227, p<0.001), 30% (3430 vs 2390, p p<0.001) of AS, aprelimast and MTX initiation, respectively, and an increase of 173% (1708 vs 4671, p=0.11) of HCQ initiation. No decrease for the renewal of B/TST was observedConclusion:During the epidemic’s peak, initiation of AS, MTX, biotherapies (except for tocilizumab), and JAKi dramatically decreased without impacting their renewal. Two treatments were mainly initiated, tocilizumab probably due to a switch from intravenous to subcutaneous injection and HCQ in relation to its presumably effect on COVID-19. Overall, recommendations from scientific societies have been followed.Disclosure of Interests:None declared
Collapse
|
34
|
Descamps V, Deschamps L, El Khalifa J, Groh M, Gibier JB, Lefèvre G, Taillé C. Eosinophilic vasculitis associated with persistent dupilumab-induced hypereosinophilia in severe asthma. Respir Med Res 2021; 79:100821. [PMID: 33984814 DOI: 10.1016/j.resmer.2021.100821] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/09/2021] [Revised: 04/01/2021] [Accepted: 04/08/2021] [Indexed: 01/01/2023]
Affiliation(s)
- V Descamps
- Groupe Hospitalier Universitaire AP-HP Nord-Université de Paris, Hôpital Bichat, Service de Dermatologie, Paris, France
| | - L Deschamps
- Groupe Hospitalier Universitaire AP-HP Nord-Université de Paris, Hôpital Bichat, Service de Pathologie, Paris, France
| | - J El Khalifa
- Groupe Hospitalier Universitaire AP-HP Nord-Université de Paris, Hôpital Bichat, Service de Dermatologie, Paris, France
| | - M Groh
- Department of Internal Medicine, Hôpital Foch, Suresnes, France; National Reference Center for Hypereosinophilic syndromes (CEREO), France
| | - J-B Gibier
- Centre de Biologie et Pathologie, CHU de Lille, Lille, France
| | - G Lefèvre
- National Reference Center for Hypereosinophilic syndromes (CEREO), France; Institut d'Immunologie, CHU de Lille, U1286-INFINITE-Institute for Translational Research in Inflammation, University Lille, Inserm, CHU de Lille, Lille, France
| | - C Taillé
- Groupe Hospitalier Universitaire AP-HP Nord-Université de Paris, Hôpital Bichat, Service de Pneumologie et Centre de Référence constitutif des Maladies Pulmonaires Rares; Inserm UMR 1152, Paris, France.
| |
Collapse
|
35
|
Weill A, Delyon J, Descamps V, Deschamps L, Dinulescu M, Dupuy A, Célérier P, Nardin C, Aubin F, Le Corre Y, Heidelberger V, Maubec E, Malissen N, Longvert C, Machet L, Gounant V, Brosseau S, Bonniaud B, Jeudy G, Psimaras D, Doucet L, Lebbe C, Zalcman G, De Masson A, Baroudjian B, Leonard-Louis S, Hervier B, Brunet-Possenti F. Treatment strategies and safety of rechallenge in the setting of immune checkpoint inhibitors-related myositis: A national multicenter study. Rheumatology (Oxford) 2021; 60:5753-5764. [PMID: 33725115 DOI: 10.1093/rheumatology/keab249] [Citation(s) in RCA: 12] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/21/2020] [Accepted: 03/04/2021] [Indexed: 11/12/2022] Open
Abstract
OBJECTIVES The occurrence of immune-related myositis (irM) is increasing, yet there are no therapeutic guidelines. We sought to analyze the current therapeutic strategies of irM and evaluate the outcomes of immune checkpoint inhibitors (ICI) rechallenge. METHODS We conducted a nationwide retrospective study between April 2018 and March 2020 including irM without myocardial involvement. Depending on the presence of cutaneous signs or unusual histopathological features, patients were classified into two groups: typical or atypical irM. Therapeutic strategies were analyzed in both groups. The modalities and outcomes of ICI rechallenge were reviewed. RESULTS Among the 20 patients, 16 presented typical irM. Regardless of severity, most typical irM were treated with steroid monotherapy (n = 14/16) and all had a complete response within ≤ 3 weeks. The efficacy of oral steroids for non-severe typical irM (n = 10) was the same with low-dose (≤ 0.5 mg/kg/day) or high-dose (1 mg/kg/day). Severe typical irM were successfully treated with intravenous methylprednisolone. Atypical irM (n = 4) had a less favorable evolution, including one irM-related death, and required heavy immunosuppression. ICI were safely reintroduced in 9 patients presenting a moderate (n = 6) or a severe (n = 3) irM. CONCLUSION Our data highlight that steroid monotherapy is an effective treatment for typical irM, either with prednisone or with intravenous methylprednisone pulses depending on the severity. The identification of unusual features is important in determining the initial therapeutic strategy. The outcomes of rechallenged patients are in favor of a safe reintroduction of ICI following symptom resolution and CK normalization in moderate and severe forms of irM.
Collapse
Affiliation(s)
- Amandine Weill
- Department of Dermatology, Hôpital Bichat, AP-HP, Université de Paris, Paris, France
| | - Julie Delyon
- Department of Dermatology, Hôpital Saint Louis, AP-HP, Université de Paris, Paris, France
| | - Vincent Descamps
- Department of Dermatology, Hôpital Bichat, AP-HP, Université de Paris, Paris, France
| | - Lydia Deschamps
- Department of Pathology, Hôpital Bichat, AP-HP, Université de Paris, Paris, France
| | - Monica Dinulescu
- Department of Dermatology, CHU de Rennes, Université de Rennes, Rennes, France
| | - Alain Dupuy
- Department of Dermatology, CHU de Rennes, Université de Rennes, Rennes, France
| | | | - Charlee Nardin
- Department of Dermatology, CHU de Besançon, Université de Franche Comté, Besançon, France
| | - François Aubin
- Department of Dermatology, CHU de Besançon, Université de Franche Comté, Besançon, France
| | - Yannick Le Corre
- Department of Dermatology, CHU d'Angers, Université LUNAM, Angers, France
| | - Valentine Heidelberger
- Department of Dermatology, Hôpital Avicenne, AP-HP, Université Sorbonne Paris Nord, Bobigny, France
| | - Eve Maubec
- Department of Dermatology, Hôpital Avicenne, AP-HP, Université Sorbonne Paris Nord, Bobigny, France
| | - Nausicaa Malissen
- Department of Dermatology, Hôpital La Timone, AP-HM, Université d'Aix-Marseille, Marseille, France
| | - Christine Longvert
- Department of Dermatology, Hôpital Ambroise-Paré, AP-HP, Boulogne-Billancourt, France
| | - Laurent Machet
- Dermatology Department, CHRU de Tours, Université de Tours, Tours, France
| | - Valérie Gounant
- Department of Thoracic Oncology, Hôpital Bichat, AP-HP, Université de Paris, Paris, France
| | - Solenne Brosseau
- Department of Thoracic Oncology, Hôpital Bichat, AP-HP, Université de Paris, Paris, France
| | - Bertille Bonniaud
- Department of Dermatology, Hôpital universitaire de Dijon, Dijon, France
| | - Géraldine Jeudy
- Department of Dermatology, Hôpital universitaire de Dijon, Dijon, France
| | - Dimitri Psimaras
- Department of Neurology, Hôpital La Pitié Salpétrière, AP-HP, Université Sorbonne Paris Centre, Paris, France
| | - Ludovic Doucet
- Department of Oncology, Hôpital Saint Louis, AP-HP, Université 7, Paris, France
| | - Céleste Lebbe
- Department of Dermatology, Hôpital Saint Louis, AP-HP, Université de Paris, Paris, France
| | - Gérard Zalcman
- Department of Thoracic Oncology, Hôpital Bichat, AP-HP, Université de Paris, Paris, France
| | - Adèle De Masson
- Department of Dermatology, Hôpital Saint Louis, AP-HP, Université de Paris, Paris, France
| | - Barouyr Baroudjian
- Department of Dermatology, Hôpital Saint Louis, AP-HP, Université de Paris, Paris, France
| | - Sarah Leonard-Louis
- Department of Neuropathology, Hôpital La Pitié Salpétrière, AP-HP, Université Sorbonne Paris Centre, Paris, France
| | - Baptiste Hervier
- Department of Internal Medicine, Hôpital Saint Louis, AP-HP, Université de Paris, Paris, France
| | | | | |
Collapse
|
36
|
Fournier M, Faille D, Dossier A, Mageau A, Nicaise Roland P, Ajzenberg N, Borie R, Bouadma L, Bunel V, Castier Y, Choquet C, Crestani B, Daugas E, Deconinck L, Descamps D, Descamps V, Dieudé P, Ducrocq G, Faucher N, Goulenok T, Guidoux C, Khalil A, Lavallée P, Lescure FX, Lortat-Jacob B, Mal H, Mutuon P, Pellenc Q, Steg PG, Taille C, Timsit JF, Yazdanpanah Y, Papo T, Sacré K. Arterial Thrombotic Events in Adult Inpatients With COVID-19. Mayo Clin Proc 2021; 96:295-303. [PMID: 33549252 PMCID: PMC7691140 DOI: 10.1016/j.mayocp.2020.11.018] [Citation(s) in RCA: 39] [Impact Index Per Article: 13.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/22/2020] [Revised: 10/21/2020] [Accepted: 11/19/2020] [Indexed: 12/21/2022]
Abstract
OBJECTIVE To evaluate the clinical course of and risk factors for arterial thrombotic events in adult inpatients with coronavirus disease 2019 (COVID-19). METHODS All consecutive adult patients admitted for COVID-19 infection in a referral center in France and discharged from the hospital between April 1 and April 30, 2020, were included. All arterial thrombotic events that occurred through discharge were considered for analysis. Epidemiologic, demographic, clinical, laboratory, treatment, and outcome data were extracted from electronic medical records with use of a standardized data collection form. RESULTS Overall, 531 COVID-19+ patients were analyzed. Among them, 30 (5.6%) experienced arterial thrombotic events. Arterial thrombotic events in the setting of COVID-19 infection happened at a median of 11 (5-20) days after the first symptoms of infection; occurred in high-risk patients according to traditional cardiovascular risk factors; had an atypical pattern, such as thrombosis of the aorta, upper limb, or renal arteries or cerebral microvasculopathy in 7 (23.3%) cases; and were associated with an in-hospital mortality rate of 40%. Arterial thrombotic events increased the risk of death by 3-fold in COVID-19+ patients (hazard ratio, 2.96; 95% CI, 1.4 to 4.7; P=.002). A subdistribution survival hazard model showed that a concentration of D-dimer above 1250 ng/mL increased the risk of arterial thrombotic events in COVID-19+ patients by more than 7 (subdistribution hazard ratio, 7.68; 95% CI, 2.9 to 20.6; P<.001). CONCLUSION A dramatically high rate of in-hospital death was observed in patients who suffered arterial thrombotic events in the setting of COVID-19 infection. A D-dimer level above 1250 ng/mL at entry may identify COVID-19+ patients at risk for arterial thrombotic events.
Collapse
Affiliation(s)
- Morgane Fournier
- Département de Médecine Interne, Hôpital Bichat, Assistance Publique Hôpitaux de Paris, Université de Paris, France
| | - Dorothée Faille
- Département d'Hémostase, Hôpital Bichat, Assistance Publique Hôpitaux de Paris, Université de Paris, France
| | - Antoine Dossier
- Département de Médecine Interne, Hôpital Bichat, Assistance Publique Hôpitaux de Paris, Université de Paris, France
| | - Arthur Mageau
- Département de Médecine Interne, Hôpital Bichat, Assistance Publique Hôpitaux de Paris, Université de Paris, France
| | - Pascale Nicaise Roland
- Département d'Immunologie, Hôpital Bichat, Assistance Publique Hôpitaux de Paris, Université de Paris, France; INSERM UMR 1152, Paris, France
| | - Nadine Ajzenberg
- Département d'Hémostase, Hôpital Bichat, Assistance Publique Hôpitaux de Paris, Université de Paris, France
| | - Raphael Borie
- Département Pneumologie A, Hôpital Bichat, Assistance Publique Hôpitaux de Paris, Université de Paris, France
| | - Lila Bouadma
- Département de Réanimation Médicale, Hôpital Bichat, Assistance Publique Hôpitaux de Paris, Université de Paris, France
| | - Vincent Bunel
- Département de Pneumologie B, Hôpital Bichat, Assistance Publique Hôpitaux de Paris, Université de Paris, France
| | - Yves Castier
- Département de Chirurgie Vasculaire et Thoracique, Hôpital Bichat, Assistance Publique Hôpitaux de Paris, Université de Paris, France
| | - Christophe Choquet
- Département des Urgences, Hôpital Bichat, Assistance Publique Hôpitaux de Paris, Université de Paris, France
| | - Bruno Crestani
- Département Pneumologie A, Hôpital Bichat, Assistance Publique Hôpitaux de Paris, Université de Paris, France
| | - Eric Daugas
- Département de Néphrologie, Hôpital Bichat, Assistance Publique Hôpitaux de Paris, Université de Paris, France
| | - Laurene Deconinck
- Département de Maladies Infectieuse, Hôpital Bichat, Assistance Publique Hôpitaux de Paris, Université de Paris, France
| | - Diane Descamps
- Département de Virologie, Hôpital Bichat, Assistance Publique Hôpitaux de Paris, Université de Paris, France
| | - Vincent Descamps
- Département de Dermatologie, Hôpital Bichat, Assistance Publique Hôpitaux de Paris, Université de Paris, France
| | - Philippe Dieudé
- Département de Rhumatologie, Hôpital Bichat, Assistance Publique Hôpitaux de Paris, Université de Paris, France
| | - Gregory Ducrocq
- Département de Cardiologie, Hôpital Bichat, Assistance Publique Hôpitaux de Paris, Université de Paris, France
| | - Nathalie Faucher
- Département de Gériatrie, Hôpital Bichat, Assistance Publique Hôpitaux de Paris, Université de Paris, France
| | - Tiphaine Goulenok
- Département de Médecine Interne, Hôpital Bichat, Assistance Publique Hôpitaux de Paris, Université de Paris, France
| | - Céline Guidoux
- Département de Neurologie, Hôpital Bichat, Assistance Publique Hôpitaux de Paris, Université de Paris, France
| | - Antoine Khalil
- Département de Radiologie, Hôpital Bichat, Assistance Publique Hôpitaux de Paris, Université de Paris, France
| | - Philippa Lavallée
- Département de Neurologie, Hôpital Bichat, Assistance Publique Hôpitaux de Paris, Université de Paris, France
| | - François Xavier Lescure
- Département de Maladies Infectieuse, Hôpital Bichat, Assistance Publique Hôpitaux de Paris, Université de Paris, France
| | - Brice Lortat-Jacob
- Département d'Anesthésie-Réanimation, Hôpital Bichat, Assistance Publique Hôpitaux de Paris, Université de Paris, France
| | - Hervé Mal
- Département de Pneumologie B, Hôpital Bichat, Assistance Publique Hôpitaux de Paris, Université de Paris, France
| | - Pierre Mutuon
- Département d'Information Médicale, Hôpital Bichat, Assistance Publique Hôpitaux de Paris, Université de Paris, France
| | - Quentin Pellenc
- Département de Chirurgie Vasculaire et Thoracique, Hôpital Bichat, Assistance Publique Hôpitaux de Paris, Université de Paris, France
| | - Philippe Gabriel Steg
- Département de Cardiologie, Hôpital Bichat, Assistance Publique Hôpitaux de Paris, Université de Paris, France
| | - Camille Taille
- Département Pneumologie A, Hôpital Bichat, Assistance Publique Hôpitaux de Paris, Université de Paris, France
| | - Jean Francois Timsit
- Département de Réanimation Médicale, Hôpital Bichat, Assistance Publique Hôpitaux de Paris, Université de Paris, France
| | - Yazdan Yazdanpanah
- Département de Maladies Infectieuse, Hôpital Bichat, Assistance Publique Hôpitaux de Paris, Université de Paris, France
| | - Thomas Papo
- Département de Médecine Interne, Hôpital Bichat, Assistance Publique Hôpitaux de Paris, Université de Paris, France; INSERM U1149, Paris, France
| | - Karim Sacré
- Département de Médecine Interne, Hôpital Bichat, Assistance Publique Hôpitaux de Paris, Université de Paris, France; INSERM U1149, Paris, France.
| |
Collapse
|
37
|
Descamps V, Gautheret‐Dejean A, Pelletier A, Bonnafous P, Deschamps L, Prusty BK. Chronic persistent HHV-6B infection after sulfasalazine-induced DRESS with demonstration of HHV-6 encoded small noncoding RNAs (sncRNAs) in Crohn's-like colitis: Case report. Clin Case Rep 2021; 9:841-844. [PMID: 33598255 PMCID: PMC7869345 DOI: 10.1002/ccr3.3680] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/20/2020] [Revised: 09/08/2020] [Accepted: 09/20/2020] [Indexed: 12/18/2022] Open
Abstract
A sulfasalazine-induced DRESS (Drug Reactivation with Eosinophilia and Systemic Symptoms) was complicated by a Crohn's-like colitis. We demonstrated HHV-6 reactivation with presence of HHV-6 DNA and small noncoding RNA in colonic lesions. This observation confirms the major role of HHV-6 reactivation in DRESS manifestations and the importance of looking for HHV-6 reactivation in DRESS.
Collapse
Affiliation(s)
- Vincent Descamps
- Department of DermatologyBichat HospitalAPHP ParisParis 7 UniversityParisFrance
| | | | - Anne‐Laure Pelletier
- Department of GastroenterologyBichat HospitalAPHP ParisParis 7 UniversityParisFrance
| | | | - Lydia Deschamps
- Department of PathologyBichat HospitalAPHP ParisParis 7 UniversityParisFrance
| | - Bhupesh K. Prusty
- Institute for Virology and ImmunobiologyUniversity of WuerzburgWuerzburgGermany
| |
Collapse
|
38
|
Borie R, Savale L, Dossier A, Ghosn J, Taillé C, Visseaux B, Jebreen K, Diallo A, Tesmoingt C, Morer L, Goletto T, Faucher N, Hajouji L, Neukirch C, Phillips M, Stelianides S, Bouadma L, Brosseau S, Ottaviani S, Pluvy J, Le Pluart D, Debray MP, Raynaud-Simon A, Descamps D, Khalil A, Timsit JF, Lescure FX, Descamps V, Papo T, Humbert M, Crestani B, Dieude P, Vicaut E, Zalcman G. Glucocorticoids with low-dose anti-IL1 anakinra rescue in severe non-ICU COVID-19 infection: A cohort study. PLoS One 2020; 15:e0243961. [PMID: 33326457 PMCID: PMC7743937 DOI: 10.1371/journal.pone.0243961] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/18/2020] [Accepted: 12/02/2020] [Indexed: 01/08/2023] Open
Abstract
BACKGROUND The optimal treatment for patients with severe coronavirus-19 disease (COVID-19) and hyper-inflammation remains debated. MATERIAL AND METHODS A cohort study was designed to evaluate whether a therapeutic algorithm using steroids with or without interleukin-1 antagonist (anakinra) could prevent death/invasive ventilation. Patients with a ≥5-day evolution since symptoms onset, with hyper-inflammation (CRP≥50mg/L), requiring 3-5 L/min oxygen, received methylprednisolone alone. Patients needing ≥6 L/min received methylprednisolone + subcutaneous anakinra daily either frontline or in case clinical deterioration upon corticosteroids alone. Death rate and death or intensive care unit (ICU) invasive ventilation rate at Day 15, with Odds Ratio (OR) and 95% CIs, were determined according to logistic regression and propensity scores. A Bayesian analysis estimated the treatment effects. RESULTS Of 108 consecutive patients, 70 patients received glucocorticoids alone. The control group comprised 63 patients receiving standard of care. In the corticosteroid±stanakinra group (n = 108), death rate was 20.4%, versus 30.2% in the controls, indicating a 30% relative decrease in death risk and a number of 10 patients to treat to avoid a death (p = 0.15). Using propensity scores a per-protocol analysis showed an OR for COVID-19-related death of 0.9 (95%CI [0.80-1.01], p = 0.067). On Bayesian analysis, the posterior probability of any mortality benefit with corticosteroids+/-anakinra was 87.5%, with a 7.8% probability of treatment-related harm. Pre-existing diabetes exacerbation occurred in 29 of 108 patients (26.9%). CONCLUSION In COVID-19 non-ICU inpatients at the cytokine release phase, corticosteroids with or without anakinra were associated with a 30% decrease of death risk on Day 15.
Collapse
Affiliation(s)
- Raphael Borie
- Pulmonology and Thoracic Oncology Department, University Hospital Bichat-Claude Bernard, AP-HP, Université de Paris, Paris, France
| | - Laurent Savale
- Pulmonology Department, Kremlin-Bicêtre University Hospital, AP-HP, Paris-Saclay University, Kremlin-Bicêtre, France
| | - Antoine Dossier
- Internal Medicine Department, University Hospital Bichat-Claude Bernard, AP-HP, Université de Paris, Paris, France
| | - Jade Ghosn
- Infectious Disease Department, University Hospital Bichat-Claude Bernard, AP-HP, Université de Paris, Paris, France
| | - Camille Taillé
- Pulmonology and Thoracic Oncology Department, University Hospital Bichat-Claude Bernard, AP-HP, Université de Paris, Paris, France
| | - Benoit Visseaux
- Virology Department, University Hospital Bichat-Claude Bernard, AP-HP, Université de Paris, Paris, France
| | - Kamel Jebreen
- Biostatistics and Clinical Research Department, University Hospital Lariboisière, AP-HP, Université de Paris, Paris, France
| | - Abourahmane Diallo
- Biostatistics and Clinical Research Department, University Hospital Lariboisière, AP-HP, Université de Paris, Paris, France
| | - Chloe Tesmoingt
- Pharmacy Department, University Hospital Bichat-Claude Bernard, AP-HP, Université de Paris, Paris, France
| | - Lise Morer
- Pulmonology and Thoracic Oncology Department, University Hospital Bichat-Claude Bernard, AP-HP, Université de Paris, Paris, France
| | - Tiphaine Goletto
- Pulmonology and Thoracic Oncology Department, University Hospital Bichat-Claude Bernard, AP-HP, Université de Paris, Paris, France
| | - Nathalie Faucher
- Geriatrics Department, University Hospital Bichat-Claude Bernard, AP-HP, Université de Paris, Paris, France
| | - Linda Hajouji
- Pulmonology and Thoracic Oncology Department, University Hospital Bichat-Claude Bernard, AP-HP, Université de Paris, Paris, France
| | - Catherine Neukirch
- Pulmonology and Thoracic Oncology Department, University Hospital Bichat-Claude Bernard, AP-HP, Université de Paris, Paris, France
| | - Mathilde Phillips
- Pulmonology and Thoracic Oncology Department, University Hospital Bichat-Claude Bernard, AP-HP, Université de Paris, Paris, France
| | - Sandrine Stelianides
- Pulmonology and Thoracic Oncology Department, University Hospital Bichat-Claude Bernard, AP-HP, Université de Paris, Paris, France
| | - Lila Bouadma
- Medical and infectious Diseases ICU, Intensive Care Department, University Hospital Bichat-Claude Bernard, AP-HP, Université de Paris, Paris, France
| | - Solenn Brosseau
- Pulmonology and Thoracic Oncology Department, University Hospital Bichat-Claude Bernard, AP-HP, Université de Paris, Paris, France
| | - Sébastien Ottaviani
- Rheumatology Department, University Hospital Bichat-Claude Bernard, AP-HP, Université de Paris, Paris, France
| | - Johan Pluvy
- Pulmonology and Thoracic Oncology Department, University Hospital Bichat-Claude Bernard, AP-HP, Université de Paris, Paris, France
| | - Diane Le Pluart
- Infectious Disease Department, University Hospital Bichat-Claude Bernard, AP-HP, Université de Paris, Paris, France
| | - Marie-Pierre Debray
- Radiology Department, University Hospital Bichat-Claude Bernard, AP-HP, Université de Paris, Paris, France
| | - Agathe Raynaud-Simon
- Pharmacy Department, University Hospital Bichat-Claude Bernard, AP-HP, Université de Paris, Paris, France
| | - Diane Descamps
- Virology Department, University Hospital Bichat-Claude Bernard, AP-HP, Université de Paris, Paris, France
| | - Antoine Khalil
- Radiology Department, University Hospital Bichat-Claude Bernard, AP-HP, Université de Paris, Paris, France
| | - Jean Francois Timsit
- Medical and infectious Diseases ICU, Intensive Care Department, University Hospital Bichat-Claude Bernard, AP-HP, Université de Paris, Paris, France
| | - Francois-Xavier Lescure
- Infectious Disease Department, University Hospital Bichat-Claude Bernard, AP-HP, Université de Paris, Paris, France
| | - Vincent Descamps
- Dermatology Department, University Hospital Bichat-Claude Bernard, AP-HP, Université de Paris, Paris, France
| | - Thomas Papo
- Internal Medicine Department, University Hospital Bichat-Claude Bernard, AP-HP, Université de Paris, Paris, France
| | - Marc Humbert
- Pulmonology Department, Kremlin-Bicêtre University Hospital, AP-HP, Paris-Saclay University, Kremlin-Bicêtre, France
| | - Bruno Crestani
- Pulmonology and Thoracic Oncology Department, University Hospital Bichat-Claude Bernard, AP-HP, Université de Paris, Paris, France
| | - Philippe Dieude
- Rheumatology Department, University Hospital Bichat-Claude Bernard, AP-HP, Université de Paris, Paris, France
| | - Eric Vicaut
- Biostatistics and Clinical Research Department, University Hospital Lariboisière, AP-HP, Université de Paris, Paris, France
| | - Gérard Zalcman
- Pulmonology and Thoracic Oncology Department, University Hospital Bichat-Claude Bernard, AP-HP, Université de Paris, Paris, France
| | | |
Collapse
|
39
|
Dutertre M, Garel B, Tournier A, Oulès B, Franck N, Kramkimel N, Klejtman T, Descamps V, Dupin N, Brunet-Possenti F, Aractingi S, Heure C, Guégan S. Syndrome d’activation macrophagique induit par l’association ipilimumab et nivolumab chez 2 patients atteints de mélanome stade IV. Ann Dermatol Venereol 2020. [DOI: 10.1016/j.annder.2020.09.465] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
40
|
Zitouni J, El Khalifa J, Abdelhedi N, Garrault L, Descamps V, Picard Dahan C. Efficacité de l’omalizumab dans l’épidermolyse bulleuse acquise. Ann Dermatol Venereol 2020. [DOI: 10.1016/j.annder.2020.09.311] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
41
|
Salle R, Chasset F, Kottler D, Picard-Dahan C, Jannic A, Mekki N, De Risi-Pugliese T, Monfort JB, Barbaud A, Francès C, Descamps V. Belimumab for refractory manifestations of cutaneous lupus: A multicenter, retrospective observational study of 16 patients. J Am Acad Dermatol 2020; 83:1816-1819. [DOI: 10.1016/j.jaad.2020.05.058] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/01/2020] [Revised: 02/16/2020] [Accepted: 05/12/2020] [Indexed: 10/24/2022]
|
42
|
Soufir N, Benfodda M, Descamps V, Gazal S, Madjlessi-Ezra N, Colomb M, Baccard M, Archimbaud A, Renard F, Fite C, Grange A, Levy-Sitbon C, Vuong V, Jehou J, Arnoult-Coudoux E, Bachoud A, Massart-Manil S, Nicaise-Bergere C, Machuel B, Schernberg C, Lami MC, Basset-Seguin N, Lebbe C, Dupin N, Wolkenstein P, Bagot M, Saiag P, Fraitag S, Bensussan A, Marinho E, Nagore E, Kumar R, Grange F. L’algorithme MELAPRED apparaît comme un outil clef du dépistage ciblé du mélanome. Ann Dermatol Venereol 2020. [DOI: 10.1016/j.annder.2020.09.015] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
43
|
Calmettes V, Lheure C, Oulès B, Franck N, Chanal J, Garel B, Klejtman T, Guégan S, Brunet-Possenti F, Descamps V, Dupin N, Aractingi S, Kramkimel N. Étude en « vie réelle » de la tolérance du traitement adjuvant par anti-PD1 dans le mélanome stade III ou IV de résection complète. Ann Dermatol Venereol 2020. [DOI: 10.1016/j.annder.2020.09.017] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
44
|
Phan C, Beneton N, Delaunay J, Reguiai Z, Boulard C, Fougerousse AC, Cinotti E, Romanelli M, Mery-Bossard L, Thomas-Beaulieu D, Parier J, Maccari F, Perrot JL, Ruer-Mulard M, Bastien M, Begon E, Samimi M, Jacobzone C, Quiles-Tsimaratos N, Descamps V, Steff M, Bilan P, Vermersch-Langlin A, Kemula M, Amazan E, Kupfer-Bessaguet I, Cottencin AC, Prignano F, Livideanu B, Gottlieb J, Beauchet A, Mahé E. Effectiveness and Safety of Anti-interleukin-17 Therapies in Elderly Patients with Psoriasis. Acta Derm Venereol 2020; 100:adv00316. [PMID: 33111960 PMCID: PMC9309849 DOI: 10.2340/00015555-3678] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Abstract
Anti-interleukin-17 agents have recently been developed for the treatment of psoriasis. This study evaluated the tolerance and effectiveness of anti-interleukin-17 agents for psoriasis in elderly patients in daily practice. A multicentre, retrospective study was performed, involving psoriatic patients aged ≥65 years who had received an anti-interleukin-17 agent, including secukinumab, ixekizumab or brodalumab. A total of 114 patients were included: 72 received secukinumab, 35 ixekizumab, and 7 brodalumab. Treatment was stopped in 32 patients (28.9%), because of relapses in 14 patients (41.2%), primary failures in 11 patients (32.4%), or adverse events in 7 patients (20.6%). The 3 most frequently reported adverse events were injection site reactions (n = 4), oral candidiasis (n = 3), and influenza-like illness (n = 3). Regarding effectiveness, 80 patients (70%) reached a Physician Global Assessment score of 0/1, 6 months after treatment initiation. In conclusion, anti-interleukin-17 therapy appears to be an effective and safe therapeutic option for psoriasis treatment in patients aged ≥ 65 years.
Collapse
Affiliation(s)
- Céline Phan
- Department of Dermatology, CH Victor Dupouy, FR-95100 Argenteuil, France. E-mail:
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
45
|
Battesti G, Descamps V. Negative tests for SARS-CoV-2 infection do not rule out its responsibility for chilblains. Br J Dermatol 2020; 183:1151. [PMID: 32790069 PMCID: PMC7436371 DOI: 10.1111/bjd.19483] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/22/2020] [Accepted: 08/10/2020] [Indexed: 12/26/2022]
Affiliation(s)
- G Battesti
- Departments of, Department of, Pathology, Bicha, 46 rue Henri Huchard, 75018, Paris, France
| | - V Descamps
- Department of, Dermatology, Bichat Hospital AP-HP, 46 rue Henri Huchard, 75018, Paris, France
| |
Collapse
|
46
|
Descamps V, Brunet-Possenti F. Monitoring of human herpesvirus 6 infection in the management of drug reaction with eosinophilia and systemic symptoms. Clin Exp Dermatol 2020; 46:351-352. [PMID: 32608082 DOI: 10.1111/ced.14362] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/23/2020] [Accepted: 06/24/2020] [Indexed: 02/06/2023]
Affiliation(s)
- V Descamps
- Department of Dermatology, Hôpital Bichat-Claude Bernard, Paris, France
| | - F Brunet-Possenti
- Department of Dermatology, Hôpital Bichat-Claude Bernard, Paris, France
| |
Collapse
|
47
|
Battesti G, El Khalifa J, Abdelhedi N, Ferre V, Bouscarat F, Picard-Dahan C, Brunet-Possenti F, Collin G, Lavaud J, Le Bozec P, Rousselot M, Tournier A, Lheure C, Couvelard A, Hacein-Bey-Abina S, Abina AM, Charpentier C, Mignot S, Nicaise P, Descamps D, Deschamps L, Descamps V. New insights in COVID-19-associated chilblains: A comparative study with chilblain lupus erythematosus. J Am Acad Dermatol 2020; 83:1219-1222. [PMID: 32622895 PMCID: PMC7332433 DOI: 10.1016/j.jaad.2020.06.1018] [Citation(s) in RCA: 33] [Impact Index Per Article: 8.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/31/2020] [Revised: 06/24/2020] [Accepted: 06/30/2020] [Indexed: 11/26/2022]
Affiliation(s)
| | | | - Nour Abdelhedi
- Department of Dermatology, Bichat Hospital, Paris, France
| | | | | | | | | | - Gilles Collin
- Department of Virology, Bichat Hospital, Paris, France
| | - Justine Lavaud
- Department of Dermatology, Bichat Hospital, Paris, France
| | | | | | | | - Coralie Lheure
- Department of Dermatology, Bichat Hospital, Paris, France
| | | | - Salima Hacein-Bey-Abina
- Unité des Technologies Chimiques et Biologiques Pour la Santé, Centre National de la Recherche Scientifique, Unité Mixte de Recherche (UTCBS CNRS UMR) 8258, Institut National de la Santé et de la Recherche Médicale (INSERM) U1267, Faculté de Pharmacie de Paris, Université de Paris, Paris, France; Clinical Immunology Laboratory, Groupe Hospitalier Universitaire Paris-Sud, Hôpital Kremlin-Bicêtre, Assistance Publique-Hôpitaux de Paris, Le-Kremlin-Bicêtre, France
| | - Amine M Abina
- Unité des Technologies Chimiques et Biologiques Pour la Santé, Centre National de la Recherche Scientifique, Unité Mixte de Recherche (UTCBS CNRS UMR) 8258, Institut National de la Santé et de la Recherche Médicale (INSERM) U1267, Faculté de Pharmacie de Paris, Université de Paris, Paris, France; Cerba Healthcare, Cerballiance-Ile-de-France Ouest, Hôpital Privé de l'Ouest Parisien, Trappes, France
| | | | - Sabine Mignot
- Department of Immunology, Bichat Hospital, Paris, France
| | | | | | | | | |
Collapse
|
48
|
Monseau G, Landon-Cardinal O, Stenzel W, Schoindre Y, Mariampillai K, Barete S, Martel C, Masseau A, Meyer A, Terrier B, Guégan S, Verneuil L, Audia S, Livideanu CB, Hachulla E, Kahn JE, Lefevre G, Maurier F, Moulis G, Papo T, Dossier A, Descamps V, Salort-Campana E, Richard MA, Bergot E, Mortier L, Costedoat-Chalumeau N, Genot S, Perez F, Piette AM, Samson M, Schleinitz N, Zénone T, Lacoste M, de Boysson H, Madaule S, Rigolet A, Champtiaux N, Hervier B, Bouvier AM, Jooste V, Léonard-Louis S, Maisonobe T, Aouba A, Benveniste O, Bienvenu B, Allenbach Y. Systematic retrospective study of 64 patients with anti-Mi2 dermatomyositis: A classic skin rash with a necrotizing myositis and high risk of malignancy. J Am Acad Dermatol 2020; 83:1759-1763. [PMID: 32244015 DOI: 10.1016/j.jaad.2020.03.058] [Citation(s) in RCA: 13] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/08/2018] [Revised: 03/18/2020] [Accepted: 03/21/2020] [Indexed: 11/28/2022]
Affiliation(s)
- Grégoire Monseau
- Département de Médecine Interne, Centre Hospitalier Universitaire de Caen, France
| | - Océane Landon-Cardinal
- Sorbonne Universités Pierre et Marie Curie, Assistance Publique-Hôpitaux de Paris, Groupe Hospitalier Pitié-Salpêtrière, Département de médecine Interne et d'immunologie clinique, France; Institut National de la Santé Et de la Recherche Médicale, Unité Mixte de Recherche 974, Paris, France; Department of Medicine, University of Montreal; Division of Rheumatology and Research Center, Centre Hospitalier de l'Université de Montréal, Quebec, Canada
| | - Werner Stenzel
- Department of Neuropathology, Charité-Universitätsmedizin, Berlin, Germany
| | - Yoland Schoindre
- Sorbonne Universités Pierre et Marie Curie, Assistance Publique-Hôpitaux de Paris, Groupe Hospitalier Pitié-Salpêtrière, Département de médecine Interne et d'immunologie clinique, France
| | - Kubéraka Mariampillai
- Sorbonne Universités Pierre et Marie Curie, Assistance Publique-Hôpitaux de Paris, Groupe Hospitalier Pitié-Salpêtrière, Département de médecine Interne et d'immunologie clinique, France; Institut National de la Santé Et de la Recherche Médicale, Unité Mixte de Recherche 974, Paris, France
| | - Stéphane Barete
- Université Pierre et Marie Curie, Groupe Hospitalier Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris, Département de Dermatologie, France
| | - Clothilde Martel
- Département de Médecine Interne et Polyclinique, Centre Hospitalier Universitaire de Limoges, France; Département de Médecine Interne-Gastroentérologie, Centre Hospitalier d'Albi, France
| | - Agathe Masseau
- Département de Médecine Interne, Centre Hospitalier Universitaire de Nantes, France
| | - Alain Meyer
- Département de Rhumatologie Centre de Référence des Maladies Autoimmunes et de Physiologie Exploration Fonctionnelle Musculaire, Hôpitaux Universitaires de Strasbourg, France
| | - Benjamin Terrier
- Service de Médecine Interne, Centre de Référence Maladies Auto-immunes et Systémiques Rares, Hôpital Cochin Université Paris Descartes, Université Paris Descartes-Sorbonne Paris Cité, France
| | - Sarah Guégan
- Faculté de médecine Paris-Descartes, Service de Dermatologie, Hôpital Cochin, Unité Institut National de la Santé Et de la Recherche Médicale U1016, Biologie cutanée, Institut Cochin, France
| | - Laurence Verneuil
- Département de Dermatologie, Centre Hospitalier Universitaire de Caen, France
| | - Sylvain Audia
- Service de Médecine Interne et Immunologie Clinique, Centre Hospitalier Universitaire de Dijon-Bourgogne, Dijon, France
| | | | - Eric Hachulla
- Centre Hospitalier Universitaire Lille, Département de Médecine Interne et Immunologie Clinique, Centre de référence des Maladies Auto-Immunes Systémiques rares du Nord et Nord-Ouest, France
| | - Jean-Emmanuel Kahn
- Département de Médecine Interne, Hôpital Foch, Fédération des Etablissements Hospitaliers & d'Aide à la Personne, Suresnes, France
| | - Guillaume Lefevre
- Centre Hospitalier Universitaire Lille, Département de Médecine Interne et Immunologie Clinique, Centre de référence des Maladies Auto-Immunes Systémiques rares du Nord et Nord-Ouest, France
| | - François Maurier
- Service de Médecine Interne et Immunologie Clinique, Hôpitaux Privés de Metz site Belle-Isle, France
| | - Guillaume Moulis
- Département de Médecine Interne, Centre d'Investigation Clinique 1436, Centre Hospitalier Universitaire de Toulouse, France; Unité Mixte de Recherche 1027 Institut National de la Santé Et de la Recherche Médicale-Université de Toulouse, France
| | - Thomas Papo
- Département de Médecine Interne, Hôpital Bichat-Claude Bernard, Assistance Publique-Hôpitaux de Paris, France
| | - Antoine Dossier
- Département de Médecine Interne, Hôpital Bichat-Claude Bernard, Assistance Publique-Hôpitaux de Paris, France
| | - Vincent Descamps
- Department of Dermatology, Bichat Hospital, Paris 7 University, France
| | - Emmanuelle Salort-Campana
- Centre de référence des maladies neuromusculaires et de la Sclérose Latérale Amyotrophique, Hôpital de la Timone, Aix-Marseille université, Filière de santé maladies rares : maladies neuromusculaires, Marseille, France
| | - Marie-Aleth Richard
- Centre d'études et de recherche sur les services de santé et la qualité de vie 3279, Research Center in Health Services and Quality of Life Aix Marseille University, Dermatology Department, Universitary Hospital Timone, Assistance Publique Hôpitaux de Marseille, Marseille, France
| | - Emmanuel Bergot
- Département de Pneumologie, Centre Hospitalier Universitaire de Caen, France
| | - Laurent Mortier
- Département de Dermatologie, Centre Hospitalier Universitaire de Lille, France
| | - Nathalie Costedoat-Chalumeau
- Service de Médecine Interne, Centre de Référence Maladies Auto-immunes et Systémiques Rares, Hôpital Cochin Université Paris Descartes, Université Paris Descartes-Sorbonne Paris Cité, France
| | - Séverine Genot
- Département Médecine Interne-Diabétologie-Endocrinologie, Centre Hospitalier de Martigues, France
| | - Florian Perez
- Département de Neurologie, Centre Hospitalier d'Albi, France
| | - Anne-Marie Piette
- Département de Médecine Interne, Hôpital Foch, Fédération des Etablissements Hospitaliers & d'Aide à la Personne, Suresnes, France
| | - Maxime Samson
- Service de Médecine Interne et Immunologie Clinique, Centre Hospitalier Universitaire de Dijon-Bourgogne, Dijon, France
| | - Nicolas Schleinitz
- Aix-Marseille université, Département de Médecine Interne, Hôpital de la Timone, Assistance Publique-Hôpitaux de Marseille, France
| | - Thierry Zénone
- Département de Médecine Interne, Centre Hospitalier de Valence, France
| | - Marie Lacoste
- Département de Médecine Interne et Polyclinique, Centre Hospitalier Universitaire de Limoges, France
| | - Hubert de Boysson
- Département de Médecine Interne, Centre Hospitalier Universitaire de Caen, France
| | - Serge Madaule
- Département de Médecine Interne-Gastroentérologie, Centre Hospitalier d'Albi, France
| | - Aude Rigolet
- Sorbonne Universités Pierre et Marie Curie, Assistance Publique-Hôpitaux de Paris, Groupe Hospitalier Pitié-Salpêtrière, Département de médecine Interne et d'immunologie clinique, France
| | - Nicolas Champtiaux
- Sorbonne Universités Pierre et Marie Curie, Assistance Publique-Hôpitaux de Paris, Groupe Hospitalier Pitié-Salpêtrière, Département de médecine Interne et d'immunologie clinique, France
| | - Baptiste Hervier
- Sorbonne Universités Pierre et Marie Curie, Assistance Publique-Hôpitaux de Paris, Groupe Hospitalier Pitié-Salpêtrière, Département de médecine Interne et d'immunologie clinique, France
| | - Anne-Marie Bouvier
- Registre Bourguignon des Cancers Digestifs, Institut National de la Santé Et de la Recherche Médicale U1231, Centre Hospitalier Universitaire Dijon-Bourgogne, Université de Bourgogne Franche Comté, Dijon, France
| | - Valérie Jooste
- Registre Bourguignon des Cancers Digestifs, Institut National de la Santé Et de la Recherche Médicale U1231, Centre Hospitalier Universitaire Dijon-Bourgogne, Université de Bourgogne Franche Comté, Dijon, France
| | - Sarah Léonard-Louis
- Sorbonne Universités Pierre et Marie Curie, Assistance Publique-Hôpitaux de Paris, Groupe Hospitalier Pitié-Salpêtrière, Département de Neuropathologie, Paris, France
| | - Thierry Maisonobe
- Sorbonne Universités Pierre et Marie Curie, Assistance Publique-Hôpitaux de Paris, Groupe Hospitalier Pitié-Salpêtrière, Département de Neuropathologie, Paris, France
| | - Achille Aouba
- Département de Médecine Interne, Centre Hospitalier Universitaire de Caen, France
| | - Olivier Benveniste
- Sorbonne Universités Pierre et Marie Curie, Assistance Publique-Hôpitaux de Paris, Groupe Hospitalier Pitié-Salpêtrière, Département de médecine Interne et d'immunologie clinique, France; Institut National de la Santé Et de la Recherche Médicale, Unité Mixte de Recherche 974, Paris, France
| | - Boris Bienvenu
- Département de Médecine Interne, Centre Hospitalier Universitaire de Caen, France
| | - Yves Allenbach
- Sorbonne Universités Pierre et Marie Curie, Assistance Publique-Hôpitaux de Paris, Groupe Hospitalier Pitié-Salpêtrière, Département de médecine Interne et d'immunologie clinique, France; Institut National de la Santé Et de la Recherche Médicale, Unité Mixte de Recherche 974, Paris, France.
| | | |
Collapse
|
49
|
Colboc H, Bazin D, Moguelet P, Reguer S, Amode R, Jouanneau C, Lucas I, Deschamps L, Descamps V, Kluger N. Chemical composition and distribution of tattoo inks within tattoo-associated keratoacanthoma. J Eur Acad Dermatol Venereol 2020; 34:e313-e315. [PMID: 31960997 DOI: 10.1111/jdv.16220] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
Affiliation(s)
- H Colboc
- Wound Healing Department, Rothschild Hospital, Sorbonne Université, Paris, France
| | - D Bazin
- CNRS, LCP, Ba340, Paris XI University, Orsay, France
| | - P Moguelet
- Department of Pathology, Tenon Hospital, Sorbonne Université, Paris, France
| | - S Reguer
- DiffAbs beamline, Synchrotron SOLEIL L'Orme des Merisiers Saint-Aubin, Synchrotron Soleil, Gif-sur-Yvette Cedex, France
| | - R Amode
- «Tattoo» Consultation, Department of Dermatology, Bichat-Claude Bernard Hospital, HUPNVS, Paris, France
| | - C Jouanneau
- UMRS 1155, Tenon Hospital, Sorbonne Université, Paris, France
| | - I Lucas
- UMR 8235, Sorbonne Université, Paris, France
| | - L Deschamps
- Department of Pathology, Bichat-Claude Bernard Hospital, HUPNVS, Paris, France
| | - V Descamps
- «Tattoo» Consultation, Department of Dermatology, Bichat-Claude Bernard Hospital, HUPNVS, Paris, France
| | - N Kluger
- «Tattoo» Consultation, Department of Dermatology, Bichat-Claude Bernard Hospital, HUPNVS, Paris, France.,Department of Dermatology, Allergology and Venereology, Helsinki University Hospital, Helsinki, Finland
| |
Collapse
|
50
|
Mazgaj M, Picard-Dahan C, Deschamps L, Marinho E, Estève E, Descamps V. Successful ustekinumab treatment in a patient with psoriasis and subacute cutaneous lupus erythematosus. Int J Dermatol 2020; 59:e118-e120. [PMID: 31957866 DOI: 10.1111/ijd.14773] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/26/2019] [Revised: 10/21/2019] [Accepted: 12/20/2019] [Indexed: 12/30/2022]
Affiliation(s)
- Magdalena Mazgaj
- Department of Dermatology, Bichat Hospital, APHP, University Paris 7, Paris, France
| | | | - Lydia Deschamps
- Department of Pathology, Bichat Hospital, APHP, University Paris 7, Paris, France
| | - Eduardo Marinho
- Department of Pathology, Bichat Hospital, APHP, University Paris 7, Paris, France
| | - Eric Estève
- Department of Dermatology, de la Source Hospital, Orléans, France
| | - Vincent Descamps
- Department of Dermatology, Bichat Hospital, APHP, University Paris 7, Paris, France
| |
Collapse
|